<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0102244830
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Anavalin
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CABAZITAXEL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11278.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EVER PHARMA JENA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EVER PHARMA JENA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 765]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jamjoom Medicine Store
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EVER Neuro Pharma GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01CD04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is&nbsp;Anavalin.&nbsp;Its common name is &quot;cabazitaxel&quot;. It belongs to a group of medicines called &quot;taxanes&quot; used to treat cancers.</p><p>Anavalin&nbsp;is used to treat prostate cancer that has progressed after having had other chemotherapy. It works by stopping cells from growing and multiplying.</p><p>As part of your treatment, you will also take a corticosteroid medicine (prednisone or prednisolone) by mouth every day. Ask your doctor to give you information about this other medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use&nbsp;Anavalin&nbsp;if:</strong></p><p>&bull;&nbsp;you are allergic (hypersensitive) to cabazitaxel, to other taxanes, or polysorbate 80 or any of the other excipients of this medicine (listed in section 6)</p><p>&bull;&nbsp;the number of your white blood cells is too low (neutrophil counts less than or equal to 1,500 /mm3),</p><p>&bull;&nbsp;you have severe abnormal liver function,</p><p>&bull;&nbsp;you have recently received or are about to receive a vaccine against yellow fever.</p><p>You should not be given&nbsp;Anavalin&nbsp;if any of the above apply to you. If you are not sure, talk to your doctor before having&nbsp;Anavalin.</p><p><strong>Warnings and precautions</strong></p><p>Before each treatment with&nbsp;Anavalin,&nbsp;you will have blood tests to check that you have enough blood cells and sufficient liver and kidney functions to receive&nbsp;Anavalin.</p><p>Tell your doctor immediately if:</p><p>&bull;&nbsp;you have fever. During treatment with&nbsp;Anavalin,&nbsp;it is more likely that your white blood cell count may be reduced. Your doctor will monitor your blood and general condition for signs of infections. He/she may give you other medicines to maintain the number of your blood cells. People with low blood counts can develop life-threatening infections. The earliest sign of infection may be fever, so if you experience fever, tell your doctor right away.</p><p>&bull;&nbsp;you have ever had any allergies. Serious allergic reactions can occur during treatment with&nbsp;Anavalin.</p><p>&bull;&nbsp;you have severe or long lasting diarrhoea, you feel sick (nausea) or you are being sick (vomiting). Any of these events could cause severe dehydration. Your doctor may need to treat you.</p><p>&bull;&nbsp;you have feeling of numbness, tingling, burning or decreased sensation in your hands or feet.</p><p>&bull;&nbsp;you have any bleeding problems from the gut or have changes in the colour of your stool or stomach pain. If the bleeding or pain is severe, your doctor will stop your treatment with&nbsp;Anavalin.&nbsp;This is because&nbsp;Anavalin&nbsp;may increase the risk of bleeding or developing holes in the gut wall.</p><p>&bull;&nbsp;you have kidney problems.</p><p>&bull;&nbsp;liver problems occur during the treatment.</p><p>&bull;&nbsp;you experience any significant increase or decrease in daily urinary volume.</p><p>&bull;&nbsp;you have blood in your urine.</p><p>If any of the above applies to you, tell your doctor immediately. Your doctor may reduce the dose of&nbsp;Anavalin&nbsp;or stop the treatment.</p><p><strong>Other medicines and&nbsp;Anavalin</strong></p><p>Please tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription. This is because some medicines can affect the way&nbsp;Anavalin&nbsp;works or&nbsp;Anavalin&nbsp;can affect how other medicines work. These medicines include the following:</p><p>&bull;&nbsp;ketoconazole, rifampicin - for infections;</p><p>&bull;&nbsp;carbamazepine, phenobarbital or phenytoin - for seizures;</p><p>&bull;&nbsp;St John&#39;s Wort (Hypericum perforatum) - herbal remedy for depression and other conditions.</p><p>&bull;&nbsp;statins (such as simvastatin, lovastatin, atorvastatin, rosuvastatin, or pravastatin) - for reducing the cholesterol in your blood</p><p>&bull;&nbsp;valsartan - for hypertension</p><p>&bull;&nbsp;repaglinide - for diabetes</p><p>Talk to your doctor before getting vaccinations while you are receiving&nbsp;Anavalin.</p><p><strong>Pregnancy, breast-feeding and&nbsp;fertility</strong></p><p>Anavalin&nbsp;should not be used in pregnant women or women of childbearing age not usingcontraception.</p><p>Anavalin&nbsp;should not be used during breast-feeding.</p><p>Use a condom during sex if your partner is or could become pregnant.&nbsp;Anavalin&nbsp;could be present in your semen and may affect the foetus. You are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because&nbsp;Anavalin&nbsp;may alter male fertility.</p><p><strong>Driving and using machines</strong></p><p>You may feel tired or dizzy when having this medicine. If this happens, do not drive or use any tools or machines until you feel better.</p><p><strong>Anavalin&nbsp;contains&nbsp;ethanol (alcohol)</strong></p><p>Vial 4.5 ml</p><p>This medicine contains 888.8 mg of alcohol (ethanol) in each vial. The amount of 4.5 ml in this medicine is equivalent to&nbsp;22.5 ml beer or 9.4 ml wine.&nbsp;</p><p>&nbsp;</p><p>Vial 5 ml</p><p>This medicine contains 987.5 mg of alcohol (ethanol) in each vial. The amount of 5 ml in this medicine is equivalent to&nbsp;25 ml beer or&nbsp;10.4 ml wine.&nbsp;</p><p>&nbsp;</p><p>Vial 6 ml</p><p>This medicine contains 1185 mg of alcohol (ethanol) in each vial. The amount of 6 ml in this medicine is equivalent to 30&nbsp;ml beer or&nbsp;12.5&nbsp;ml wine.&nbsp;</p><p>&nbsp;</p><p>The amount of alcohol in this medicine is not likely to have an effect in adults and adolescents.</p><p>The amount of alcohol in this medicine may alter the effects of other medicines. Talk to your doctor or pharmacist if you are taking other medicines.</p><p>&nbsp;</p><p>If you are addicted to alcohol, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Instructions for use</strong></p><p>Anti-allergic medicines will be given to you before you have&nbsp;Anavalin&nbsp;to reduce the risk of allergic reactions.</p><p>&bull;&nbsp;Anavalin&nbsp;be given to you by a doctor or a nurse.</p><p>&bull;&nbsp;Anavalin&nbsp;must be prepared (diluted) before it is given. Practical information for handling and administration of&nbsp;Anavalin&nbsp;for doctors, nurses and pharmacists is provided with this leaflet.</p><p>&bull;&nbsp;Anavalin&nbsp;will be given by a drip (infusion) into one of your veins (intravenous use) in hospital for about an hour.</p><p>&bull;&nbsp;As part of your treatment, you will also take a corticosteroid medicine (prednisone or prednisolone) by mouth every day.</p><p><strong>How much and how often to have</strong></p><p>&bull;&nbsp;The usual dose depends on your body surface area. Your doctor will calculate your body surface area in square meters (m2) and will decide the dose you should have.</p><p>&bull;&nbsp;You will usually have an infusion once every 3 weeks.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss these with you and will explain the potential risks and benefits of your treatment.</p><p><strong>See a doctor immediately if you notice any of the following side effects:</strong></p><p>&bull;&nbsp;fever (high temperature). This is very common (may affect more than 1 in 10 people).</p><p>&bull;&nbsp;severe loss of body fluids (dehydration). This is common (may affect up to 1 in 10 people). This can occur if you have severe or long-lasting diarrhoea, or fever, or if you are being sick (vomiting).</p><p>&bull;&nbsp;severe stomach pain or stomach pain that doesn&#39;t go away. This can occur if you have a hole in the stomach, food pipe, gut or bowel (gastrointestinal perforation). This can lead to death.</p><p>If any of the above applies to you, tell your doctor immediately.</p><p><strong>Other side-effects include:</strong></p><p><strong>Very common</strong>&nbsp;(may affect more than 1 in 10 people):</p><p>&bull;&nbsp;decrease in the number of red (anaemia), or white blood cells (which are important in fighting infection)</p><p>&bull;&nbsp;decrease in the number of platelets (which results in increased risk of bleeding)</p><p>&bull;&nbsp;loss of appetite (anorexia)</p><p>&bull;&nbsp;alteration in sense of taste</p><p>&bull;&nbsp;shortness of breath</p><p>&bull;&nbsp;cough</p><p>&bull;&nbsp;stomach upsets including feeling sick (nausea), being sick (vomiting), diarrhoea or constipation</p><p>&bull;&nbsp;abdominal pain</p><p>&bull;&nbsp;short term hair loss (in most cases normal hair growth should return)</p><p>&bull;&nbsp;back pain</p><p>&bull;&nbsp;joint pain</p><p>&bull;&nbsp;blood in the urine</p><p>&bull;&nbsp;feeling tired, weak or lack of energy.</p><p><strong>Common</strong>&nbsp;(may affect up to 1 in 10 people):</p><p>&bull;&nbsp;urinary tract infection</p><p>&bull;&nbsp;lack of white blood cells associated with fever and infection</p><p>&bull;&nbsp;feeling of numbness, tingling, burning or decreased sensations in hands and feet</p><p>&bull;&nbsp;dizziness</p><p>&bull;&nbsp;headache</p><p>&bull;&nbsp;decrease or increase in blood pressure</p><p>&bull;&nbsp;uncomfortable feeling in the stomach, heart burn or belching</p><p>&bull;&nbsp;stomach pain</p><p>&bull;&nbsp;haemorrhoids</p><p>&bull;&nbsp;muscle spasm</p><p>&bull;&nbsp;painful or frequent urination</p><p>&bull;&nbsp;urinary incontinence</p><p>&bull;&nbsp;kidney disease or problems</p><p>&bull;&nbsp;sore in the mouth or on lips</p><p>&bull;&nbsp;infections or risk of infections</p><p>&bull;&nbsp;high blood sugar</p><p>&bull;&nbsp;low blood potassium</p><p>&bull;&nbsp;mental confusion</p><p>&bull;&nbsp;feeling anxious</p><p>&bull;&nbsp;abnormal feeling or loss of sensation or pain in hands and feet</p><p>&bull;&nbsp;ringing in the ear</p><p>&bull;&nbsp;trouble with balance</p><p>&bull;&nbsp;rapid or irregular heartbeat</p><p>&bull;&nbsp;blood clot in the leg</p><p>&bull;&nbsp;skin feeling hot or flushed</p><p>&bull;&nbsp;pain in mouth or throat</p><p>&bull;&nbsp;rectal bleeding</p><p>&bull;&nbsp;redness of the skin</p><p>&bull;&nbsp;muscle discomfort, aches or pain</p><p>&bull;&nbsp;swelling of the feet or legs</p><p>&bull;&nbsp;chills.</p><p><strong>Uncommon</strong>&nbsp;(may affect up to 1 in 100 people):</p><p>&bull;&nbsp;inflammation of the bladder, which can occur when your bladder has been previously exposed to radiation therapy (cystitis due to radiation recall phenomenon).</p><p><strong>Frequency not known</strong>&nbsp;(cannot be estimated from the available data):</p><p>&bull;&nbsp;interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly&nbsp;via the&nbsp;national reporting system listed in&nbsp;Appendix V.&nbsp;By reporting side effects,&nbsp;you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&minus;&nbsp;Please contact the relevant competent&nbsp;authority.</p><p>&bull;&nbsp;The National Pharmacovigilance Centre&nbsp;(NPC):</p><p>&minus;&nbsp;SFDA Call Center:&nbsp;19999</p><p>&minus;&nbsp;E-mail:&nbsp;npc.drug@sfda.gov.sa&nbsp;</p><p>&minus;&nbsp;Website:&nbsp;https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the outer carton and on the label of the vials after EXP. The expiry date refers to the last day of that month.</p><p>This medicinal product does not require any special storage conditions.</p><p>Do not&nbsp;freeze.</p><p>Multi-dose vials:&nbsp;Chemical, physical and microbiological stability of the solution after first opening has been demonstrated for&nbsp;28&nbsp;days&nbsp;below&nbsp;25&deg;C.&nbsp;Anavalin&nbsp;is suitable for multi-dose use.</p><p>Information about storage and the time to use&nbsp;Anavalin,&nbsp;once it has been diluted and is ready to use, are described in the section &quot;PRACTICAL INFORMATION FOR MEDICAL OR HEALTHCARE PROFESSIONALS ON PREPARATION, ADMINISTRATION AND HANDLING OF&nbsp;ANAVALIN&quot;.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cabazitaxel. One ml of&nbsp;the&nbsp;concentrate&nbsp;for solution for infusioncontains&nbsp;cabazitaxel monohydrate or anhydrous equivalent to&nbsp;10 mg cabazitaxel.&nbsp;</p><p>Each vial of 4.5 ml of concentrate for solution for infusion contains cabazitaxel monohydrate or anhydrous equivalent to 45 mg cabazitaxel.</p><p>Each vial of 5 ml of concentrate for solution for infusion contains cabazitaxel monohydrate or anhydrous equivalent to 50 mg cabazitaxel.</p><p>Each vial of 6 ml of concentrate for solution for infusion contains cabazitaxel monohydrate or anhydrous equivalent to 60 mg cabazitaxel.</p><p>Anavalin&nbsp;10 mg/ml&nbsp;concentrate for solution for infusion&nbsp;contains an overfill. This overfill ensures that there is extractable volume of 4.5 ml, 5 ml or 6 ml containing 10 mg/ml cabazitaxel.</p><p>The other ingredients are&nbsp;polysorbate 80;&nbsp;macrogol;&nbsp;citric acid;&nbsp;and ethanol, anhydrous&nbsp;(see section 2 &quot;Anavalin&nbsp;contains alcohol&quot;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Anavalin is a concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear slightly yellow oily solution.
One pack of Anavalin contains:
Clear glass vial closed with a grey bromobutyl rubber stopper sealed by an aluminium cap with a plastic flip-off cover containing 4.5 ml (5 ml or 6 ml) concentrate.
Vials may or may not be sheathed in a protective sleeve.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EVER Valinject GmbH</p><p>Oberburgau 3</p><p>4866 Unterach am Attersee</p><p>Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Feb 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>اسم&nbsp;الدواء&nbsp;هو&nbsp;أنافالين.&nbsp;الاسم&nbsp;الشائع&nbsp;هو&nbsp;&quot;كابازيتاكسيل&quot;.&nbsp;ينتمي&nbsp;إلى&nbsp;مجموعة&nbsp;الأدوية&nbsp;المسماة&quot;تاكسانات&quot;&nbsp;المستخدمة&nbsp;لعلاج&nbsp;السرطانات.</p><p>يستخدم&nbsp;أنافالين&nbsp;لعلاج&nbsp;سرطان&nbsp;البروستاتا&nbsp;الذي&nbsp;تطور&nbsp;بعد&nbsp;أن&nbsp;خضع&nbsp;لعلاج&nbsp;كيميائي&nbsp;آخر.&nbsp;وهويعمل&nbsp;عن&nbsp;طريق&nbsp;منع&nbsp;الخلايا&nbsp;من&nbsp;النمو&nbsp;والتكاثر.</p><p>كجزء&nbsp;من&nbsp;علاجك،&nbsp;ستتناول&nbsp;أيضًا&nbsp;دواء&nbsp;كورتيكوستيرويد&nbsp;(بريدنيزون&nbsp;أو&nbsp;بريدنيزولون)&nbsp;عن&nbsp;طريق&nbsp;الفمكل&nbsp;يوم.&nbsp;اطلب&nbsp;من&nbsp;طبيبك&nbsp;منحك&nbsp;معلومات&nbsp;عن&nbsp;هذا&nbsp;الدواء&nbsp;الآخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;&nbsp;إذا كنت تعاني من&nbsp;حساسية&nbsp;(حساسية شديدة)&nbsp;من&nbsp;كابازيتاكسيل،&nbsp;أو&nbsp;تاكسانات&nbsp;أخرى،&nbsp;أوبولي&nbsp;سوربات&nbsp;80&nbsp;أو&nbsp;أي&nbsp;من&nbsp;السواغات&nbsp;الأخرى&nbsp;لهذا&nbsp;الدواء&nbsp;(المدرجة&nbsp;في&nbsp;القسم&nbsp;6).</p><p>&bull;&nbsp;عدد&nbsp;خلايا&nbsp;الدم&nbsp;البيضاء&nbsp;لديك&nbsp;منخفض&nbsp;جدًا&nbsp;(العدلة&nbsp;أقل&nbsp;من&nbsp;أو&nbsp;تساوي&nbsp;1500/&nbsp;مم3)</p><p>&bull;&nbsp;وظائف الكبد غير طبيعية.</p><p>&bull;&nbsp;تلقيت&nbsp;مؤخرًا&nbsp;أو&nbsp;على&nbsp;وشك&nbsp;تلقي&nbsp;لقاح&nbsp;ضد&nbsp;الحمى&nbsp;الصفراء.</p><p>&nbsp;</p><p>لا&nbsp;ينبغي&nbsp;إعطاؤك أنافالين&nbsp;إذا&nbsp;كان&nbsp;أي&nbsp;مما&nbsp;سبق&nbsp;ينطبق&nbsp;عليك.&nbsp;إذا&nbsp;لم&nbsp;تكن&nbsp;متأكدًا،&nbsp;تحدث&nbsp;إلى&nbsp;طبيبكقبل&nbsp;تناول&nbsp;أنافالين.</p><p>&nbsp;</p><p><strong>المحاذير&nbsp;والإحتياطات</strong></p><p>قبل&nbsp;كل&nbsp;علاج&nbsp;باستخدام أنافالين،&nbsp;ستخضع&nbsp;لفحوصات&nbsp;دم&nbsp;للتأكد&nbsp;من&nbsp;أن&nbsp;لديك&nbsp;ما&nbsp;يكفي&nbsp;من&nbsp;خلاياالدم&nbsp;ووظائف&nbsp;الكبد&nbsp;والكلى&nbsp;الكافية&nbsp;لتلقي&nbsp;أنافالين.</p><p>أخبر&nbsp;طبيبك&nbsp;على&nbsp;الفور&nbsp;في الحالات التالية:</p><p>&bull;&nbsp;تعاني من&nbsp;حمى.&nbsp;أثناء&nbsp;العلاج&nbsp;بأنافالين،&nbsp;من&nbsp;المرجح&nbsp;أن&nbsp;ينخفض&nbsp;عدد&nbsp;خلاياالدم&nbsp;البيضاء.&nbsp;سيراقب&nbsp;طبيبك&nbsp;حالة الدم لديك&nbsp;وحالتك&nbsp;العامة&nbsp;بحثًا&nbsp;عنعلامات&nbsp;العدوى.&nbsp;قد&nbsp;يعطيك&nbsp;أدوية&nbsp;أخرى&nbsp;للحفاظ&nbsp;على&nbsp;عدد&nbsp;خلايا&nbsp;الدم.&nbsp;يمكن&nbsp;للأشخاص&nbsp;الذين&nbsp;يعانون&nbsp;من&nbsp;انخفاض&nbsp;عدلات&nbsp;الدم&nbsp;أن&nbsp;يصابوا&nbsp;بعدوىمهددة&nbsp;للحياة.&nbsp;قد&nbsp;تكون&nbsp;الحمى&nbsp;هي&nbsp;العلامة&nbsp;الأولى&nbsp;للعدوى،&nbsp;لذلك&nbsp;إذا&nbsp;كنتتعاني&nbsp;من&nbsp;الحمى،&nbsp;أخبر&nbsp;طبيبك&nbsp;على&nbsp;الفور.</p><p>&bull;&nbsp;كنت تعاني من&nbsp;أي&nbsp;نوع&nbsp;من&nbsp;الحساسية.&nbsp;يمكن&nbsp;أن&nbsp;تحدث&nbsp;تفاعلات&nbsp;تحسسيةخطيرة&nbsp;أثناء&nbsp;العلاج&nbsp;بـ&nbsp;أنافالين.</p><p>&bull;&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;إسهال&nbsp;شديد&nbsp;أو&nbsp;طويل&nbsp;الأمد،&nbsp;تشعر&nbsp;بالغثيان&nbsp;أو&nbsp;المرض(القيء).&nbsp;يمكن&nbsp;أن&nbsp;تسبب&nbsp;أي&nbsp;من&nbsp;هذه&nbsp;الأمور&nbsp;الجفاف&nbsp;الشديد.&nbsp;قد&nbsp;يحتاجطبيبك&nbsp;إلى&nbsp;علاجك.</p><p>&bull;&nbsp;لديك&nbsp;شعور&nbsp;بالخدر&nbsp;أو&nbsp;الوخز&nbsp;أو&nbsp;الحرقان&nbsp;أو&nbsp;انخفاض&nbsp;الإحساس&nbsp;في&nbsp;يديك&nbsp;أوقدميك.</p><p>&bull;&nbsp;لديك&nbsp;أي&nbsp;مشاكل&nbsp;نزيف&nbsp;من&nbsp;القناة&nbsp;الهضمية&nbsp;أو&nbsp;تغيرات&nbsp;في&nbsp;لون&nbsp;البراز&nbsp;أو&nbsp;ألمفي&nbsp;المعدة.&nbsp;إذا&nbsp;كان&nbsp;النزيف&nbsp;أو&nbsp;الألم&nbsp;شديدًا،&nbsp;فسيتوقف&nbsp;طبيبك&nbsp;عن&nbsp;علاجك&nbsp;بـأنافالين.&nbsp;وذلك&nbsp;لأن&nbsp;أنافالين&nbsp;قد&nbsp;يزيد&nbsp;من&nbsp;خطر&nbsp;حدوث&nbsp;النزيف&nbsp;أو&nbsp;حدوث&nbsp;ثقوبفي&nbsp;جدار&nbsp;الأمعاء.</p><p>&bull;&nbsp;لديك&nbsp;مشاكل&nbsp;في&nbsp;الكلى.</p><p>&bull;&nbsp;حدوث&nbsp;مشاكل&nbsp;في&nbsp;الكبد&nbsp;أثناء&nbsp;العلاج.</p><p>&bull;&nbsp;كنت&nbsp;تواجه&nbsp;أي&nbsp;زيادة&nbsp;أو&nbsp;نقصان&nbsp;كبير&nbsp;في&nbsp;حجم&nbsp;البول&nbsp;اليومي.</p><p>&bull;&nbsp;وجود&nbsp;دم&nbsp;في&nbsp;البول.</p><p>إذا&nbsp;حدث لك&nbsp;أي&nbsp;مما&nbsp;سبق،&nbsp;أخبر&nbsp;طبيبك&nbsp;على&nbsp;الفور.&nbsp;قد&nbsp;يقوم&nbsp;طبيبك&nbsp;بتقليل&nbsp;جرعة&nbsp;أنافالين&nbsp;أو&nbsp;إيقافالعلاج.</p><p>&nbsp;</p><p><strong>الأدوية&nbsp;الأخرى&nbsp;وأنافالين</strong></p><p>يرجى&nbsp;إخبار&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;أو&nbsp;الممرضة&nbsp;إذا&nbsp;كنت&nbsp;تتناول&nbsp;أو&nbsp;تناولت&nbsp;مؤخرًا&nbsp;أي&nbsp;أدوية&nbsp;أخرى.&nbsp;وهذا&nbsp;يشمل&nbsp;الأدوية&nbsp;التي&nbsp;يتم&nbsp;الحصول&nbsp;عليها&nbsp;بدون&nbsp;وصفة&nbsp;طبية.&nbsp;هذا&nbsp;لأن&nbsp;بعض&nbsp;الأدوية&nbsp;يمكن&nbsp;أنتؤثر&nbsp;على&nbsp;طريقة&nbsp;عمل&nbsp;أنافالين&nbsp;أو&nbsp;يمكن&nbsp;لأنافالين&nbsp;أن&nbsp;يؤثر&nbsp;على&nbsp;كيفية&nbsp;عمل&nbsp;الأدوية&nbsp;الأخرى.&nbsp;تشملهذه&nbsp;الأدوية&nbsp;ما&nbsp;يلي:</p><p>&bull;&nbsp;الكيتوكونازول&nbsp;والريفامبيسين&nbsp;-&nbsp;للعدوى.</p><p>&bull;&nbsp;كاربامازيبين،&nbsp;الفينوباربيتال&nbsp;أو&nbsp;الفينيتوين&nbsp;-&nbsp;للنوبات&nbsp;؛</p><p>&bull;&nbsp;St John&#39;s Wort (Hypericum&nbsp;perforatum)&nbsp;- وهو&nbsp;علاج&nbsp;عشبي&nbsp;للاكتئابوالحالات&nbsp;الأخرى.</p><p>&bull;&nbsp;الستاتين&nbsp;(مثل&nbsp;سيمفاستاتين،&nbsp;لوفاستاتين،&nbsp;أتورفاستاتين،&nbsp;رسيوفاستاتين،&nbsp;أوبرافاستاتين) -&nbsp;لخفض&nbsp;نسبة&nbsp;الكوليسترول&nbsp;في&nbsp;الدم.</p><p>&bull;&nbsp;فالسارتان&nbsp;-&nbsp;لارتفاع&nbsp;ضغط&nbsp;الدم</p><p>&bull;&nbsp;ريباجلينيد&nbsp;-&nbsp;لمرض&nbsp;السكري</p><p>تحدث&nbsp;إلى&nbsp;طبيبك&nbsp;قبل&nbsp;الحصول&nbsp;على&nbsp;التطعيمات&nbsp;أثناء&nbsp;تلقيك&nbsp;أنافالين.</p><p>&nbsp;</p><p><strong>الحمل&nbsp;والرضاعة&nbsp;والخصوبة</strong></p><p>لا&nbsp;ينبغي&nbsp;تناول&nbsp;أنافالين&nbsp;من قبل&nbsp;النساء&nbsp;الحوامل&nbsp;أو&nbsp;النساء&nbsp;في&nbsp;سن&nbsp;الإنجاب&nbsp;ولا&nbsp;يستخدمن&nbsp;وسائلمنع&nbsp;الحمل.</p><p>لا&nbsp;ينبغي&nbsp;تناول&nbsp;أنافالين&nbsp;أثناء&nbsp;الرضاعة&nbsp;الطبيعية.</p><p>استخدم&nbsp;الواقي&nbsp;الذكري&nbsp;أثناء&nbsp;ممارسة&nbsp;الجنس&nbsp;إذا&nbsp;كانت زوجتك&nbsp;حاملاً&nbsp;أو&nbsp;يمكن&nbsp;أن&nbsp;تحمل.&nbsp;يمكنأن&nbsp;يتواجد أنافالين&nbsp;في&nbsp;السائل&nbsp;المنوي&nbsp;وقد&nbsp;يؤثر&nbsp;على&nbsp;الجنين.&nbsp;يُنصح&nbsp;بعدم&nbsp;إنجاب&nbsp;الأطفال&nbsp;خلال&nbsp;فترةالعلاج&nbsp;وحتى&nbsp;6&nbsp;أشهر&nbsp;بعد&nbsp;العلاج&nbsp;وطلب&nbsp;المشورة&nbsp;بشأن&nbsp;الحفاظ&nbsp;على&nbsp;الحيوانات&nbsp;المنوية&nbsp;قبل&nbsp;العلاجلأن&nbsp;أنافالين&nbsp;قد&nbsp;يغير&nbsp;خصوبة&nbsp;الذكور.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>القيادة&nbsp;واستخدام الآلات</strong></p><p>قد&nbsp;تشعر&nbsp;بالتعب&nbsp;أو&nbsp;الدوار&nbsp;عند&nbsp;تناول&nbsp;هذا&nbsp;الدواء.&nbsp;إذا&nbsp;حدث&nbsp;هذا،&nbsp;فلا&nbsp;تقود&nbsp;ولا&nbsp;تستخدم&nbsp;أي&nbsp;أدوات&nbsp;أوآلات&nbsp;حتى&nbsp;تشعر&nbsp;بالتحسن.</p><p>يحتوي&nbsp;أنافالين&nbsp;على&nbsp;إيثانول&nbsp;(كحول)</p><p>قنينة&nbsp;4.5&nbsp;مل</p><p>يحتوي&nbsp;هذا&nbsp;الدواء&nbsp;على&nbsp;888.8&nbsp;ملغ&nbsp;من&nbsp;الكحول&nbsp;(الإيثانول)&nbsp;في&nbsp;كل&nbsp;قنينة.&nbsp;كمية&nbsp;4.5&nbsp;مل&nbsp;في&nbsp;هذاالدواء&nbsp;تعادل&nbsp;22.5&nbsp;مل&nbsp;من&nbsp;البيرة&nbsp;أو&nbsp;9.4&nbsp;مل&nbsp;من&nbsp;النبيذ.</p><p>قنينة&nbsp;5&nbsp;مل</p><p>يحتوي&nbsp;هذا&nbsp;الدواء&nbsp;على&nbsp;987.5&nbsp;ملغ&nbsp;من&nbsp;الكحول&nbsp;(الإيثانول)&nbsp;في&nbsp;كل&nbsp;قنينة.&nbsp;كمية&nbsp;5&nbsp;مل&nbsp;في&nbsp;هذا&nbsp;الدواءتعادل&nbsp;25&nbsp;مل&nbsp;من&nbsp;البيرة&nbsp;أو&nbsp;10.4&nbsp;مل&nbsp;من&nbsp;النبيذ.</p><p>قنينة&nbsp;6&nbsp;مل</p><p>يحتوي&nbsp;هذا&nbsp;الدواء&nbsp;على&nbsp;1185&nbsp;ملغ&nbsp;من&nbsp;الكحول&nbsp;(الإيثانول)&nbsp;في&nbsp;كل&nbsp;قنينة.&nbsp;كمية&nbsp;6&nbsp;مل&nbsp;في&nbsp;هذا&nbsp;الدواءتعادل&nbsp;30&nbsp;مل&nbsp;من&nbsp;البيرة&nbsp;أو&nbsp;12.5&nbsp;مل&nbsp;من&nbsp;النبيذ.</p><p>من غير&nbsp;المحتمل&nbsp;أن&nbsp;يكون&nbsp;لكمية&nbsp;الكحول&nbsp;في&nbsp;هذا&nbsp;الدواء&nbsp;تأثير&nbsp;على&nbsp;البالغين&nbsp;والمراهقين.</p><p>قد&nbsp;تغير&nbsp;كمية&nbsp;الكحول&nbsp;في&nbsp;هذا&nbsp;الدواء&nbsp;من&nbsp;آثار&nbsp;الأدوية&nbsp;الأخرى.&nbsp;تحدث&nbsp;إلى&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;إذاكنت&nbsp;تتناول&nbsp;أدوية&nbsp;أخرى.</p><p>إذا&nbsp;كنت&nbsp;مدمناً&nbsp;على&nbsp;الكحول،&nbsp;تحدث&nbsp;إلى&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;قبل&nbsp;تناول&nbsp;هذا&nbsp;الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>تعليمات&nbsp;الاستخدام</strong></p><p>سيتم&nbsp;إعطاؤك&nbsp;الأدوية&nbsp;المضادة&nbsp;للحساسية&nbsp;قبل&nbsp;تناول&nbsp;أنافالين&nbsp;لتقليل&nbsp;مخاطر&nbsp;الحساسية.</p><p>&bull;&nbsp;يتم&nbsp;وصف&nbsp;أنافالين&nbsp;لك&nbsp;من&nbsp;قبل&nbsp;طبيب&nbsp;أو&nbsp;ممرضة.</p><p>&bull;&nbsp;يجب&nbsp;تحضير&nbsp;أنافالين&nbsp;(المخفف)&nbsp;قبل&nbsp;إعطائه.&nbsp;يتم&nbsp;توفير&nbsp;معلومات&nbsp;عمليةالتعامل&nbsp;مع&nbsp;أنافالين&nbsp;وإعطاءه&nbsp;للأطباء&nbsp;والممرضات&nbsp;والصيادلة&nbsp;مع&nbsp;هذهالنشرة.</p><p>&bull;&nbsp;سيتم&nbsp;إعطاء&nbsp;أنافالين&nbsp;عن&nbsp;طريق&nbsp;التنقيط&nbsp;(التسريب)&nbsp;في&nbsp;أحد&nbsp;عروقك(الاستخدام&nbsp;في&nbsp;الوريد)&nbsp;في&nbsp;المستشفى&nbsp;لمدة&nbsp;ساعة&nbsp;تقريباً.</p><p>&bull;&nbsp;كجزء&nbsp;من&nbsp;علاجك،&nbsp;ستتناول&nbsp;أيضًا&nbsp;دواء&nbsp;كورتيكوستيرويد&nbsp;(بريدنيزون&nbsp;أوبريدنيزولون)&nbsp;عن&nbsp;طريق&nbsp;الفم&nbsp;يومياً.</p><p>&nbsp;</p><p><strong>الجرعة والتكرار</strong></p><p>&bull;&nbsp;تعتمد&nbsp;الجرعة&nbsp;المعتادة&nbsp;على&nbsp;مساحة&nbsp;سطح&nbsp;جسمك.&nbsp;سيحسب&nbsp;طبيبك&nbsp;مساحةسطح&nbsp;جسمك&nbsp;بالمتر&nbsp;المربع&nbsp;(م2)&nbsp;وسيقرر&nbsp;الجرعة&nbsp;التي&nbsp;يجب&nbsp;أن&nbsp;تتناولها.</p><p>&bull;&nbsp;ستحصل&nbsp;عادة&nbsp;على&nbsp;حقنة&nbsp;مرة&nbsp;كل&nbsp;3&nbsp;أسابيع.</p><p>إذا&nbsp;كان&nbsp;لديك&nbsp;أي&nbsp;أسئلة&nbsp;أخرى&nbsp;حول&nbsp;استخدام&nbsp;هذا&nbsp;الدواء،&nbsp;اسأل&nbsp;طبيبك&nbsp;أو&nbsp;الصيدلي&nbsp;أو&nbsp;الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل&nbsp;جميع&nbsp;الأدوية،&nbsp;يمكن&nbsp;أن&nbsp;يسبب&nbsp;هذا&nbsp;الدواء&nbsp;آثاراً&nbsp;جانبية،&nbsp;على&nbsp;الرغم&nbsp;من&nbsp;عدم&nbsp;حدوثها&nbsp;لدىالجميع.&nbsp;سيناقش&nbsp;طبيبك&nbsp;هذه&nbsp;الأمور&nbsp;معك&nbsp;وسيشرح&nbsp;المخاطر&nbsp;والفوائد&nbsp;المحتملة&nbsp;لعلاجك.</p><p>&nbsp;</p><p><strong>راجع&nbsp;الطبيب&nbsp;فوراً&nbsp;إذا&nbsp;لاحظت&nbsp;أياً&nbsp;من&nbsp;الأعراض&nbsp;الجانبية&nbsp;التالية:</strong></p><p>&bull;&nbsp;حمى&nbsp;(ارتفاع&nbsp;في&nbsp;درجة&nbsp;الحرارة).&nbsp;هذا&nbsp;شائع&nbsp;جداً&nbsp;(قد&nbsp;يصيب&nbsp;أكثر&nbsp;من&nbsp;1&nbsp;منكل&nbsp;10&nbsp;أشخاص).</p><p>&bull;&nbsp;فقدان&nbsp;شديد&nbsp;لسوائل&nbsp;الجسم&nbsp;(الجفاف).&nbsp;هذا&nbsp;أمر&nbsp;شائع&nbsp;(قد&nbsp;يؤثر&nbsp;على&nbsp;ما&nbsp;يصلإلى&nbsp;1&nbsp;من&nbsp;كل&nbsp;10&nbsp;أشخاص).&nbsp;يمكن&nbsp;أن&nbsp;يحدث&nbsp;هذا&nbsp;إذا&nbsp;كنت&nbsp;تعاني&nbsp;منإسهال&nbsp;شديد&nbsp;أو&nbsp;طويل&nbsp;الأمد،&nbsp;أو&nbsp;حمى،&nbsp;أو&nbsp;إذا&nbsp;كنت&nbsp;مريضًا&nbsp;(القيء).</p><p>&bull;&nbsp;آلام&nbsp;شديدة&nbsp;في&nbsp;المعدة&nbsp;أو&nbsp;آلام&nbsp;في&nbsp;المعدة&nbsp;لا&nbsp;تزول.&nbsp;يمكن&nbsp;أن&nbsp;يحدث&nbsp;هذا&nbsp;إذا&nbsp;كانلديك&nbsp;ثقب&nbsp;في&nbsp;المعدة&nbsp;أو&nbsp;لديك&nbsp;أنبوب&nbsp;الطعام&nbsp;أو&nbsp;الأمعاء&nbsp;(ثقب&nbsp;في&nbsp;الجهازالهضمي).&nbsp;هذا&nbsp;يمكن&nbsp;أن&nbsp;يؤدي&nbsp;لحدوث وفاة.</p><p>&nbsp;</p><p>إذا&nbsp;انطبق&nbsp;عليك&nbsp;أي&nbsp;مما&nbsp;سبق،&nbsp;أخبر&nbsp;طبيبك&nbsp;على&nbsp;الفور.</p><p><strong>الآثار&nbsp;الجانبية&nbsp;الأخرى&nbsp;تشمل:</strong></p><p>شائعة&nbsp;جدًا&nbsp;(قد&nbsp;تظهر&nbsp;لدى&nbsp;أكثر&nbsp;من&nbsp;1&nbsp;من&nbsp;كل&nbsp;10&nbsp;أشخاص):</p><p>&bull;&nbsp;انخفاض&nbsp;في&nbsp;عدد&nbsp;كريات&nbsp;الدم&nbsp;الحمراء&nbsp;(فقر&nbsp;الدم)&nbsp;أو&nbsp;خلايا&nbsp;الدم&nbsp;البيضاء(وهي&nbsp;مهمة&nbsp;في&nbsp;مكافحة&nbsp;العدوى).</p><p>&bull;&nbsp;انخفاض&nbsp;في&nbsp;عدد&nbsp;الصفائح&nbsp;الدموية&nbsp;(مما&nbsp;يؤدي&nbsp;إلى&nbsp;زيادة&nbsp;خطر&nbsp;النزيف).</p><p>&bull;&nbsp;فقدان&nbsp;الشهية.</p><p>&bull;&nbsp;تغيير&nbsp;في&nbsp;حاسة&nbsp;التذوق</p><p>&bull;&nbsp;ضيق&nbsp;في&nbsp;التنفس</p><p>&bull;&nbsp;سعال</p><p>&bull;&nbsp;اضطرابات&nbsp;في&nbsp;المعدة&nbsp;بما&nbsp;في&nbsp;ذلك&nbsp;الشعور&nbsp;بالغثيان،&nbsp;المرض&nbsp;(القيء)،الإسهال&nbsp;أو&nbsp;الإمساك</p><p>&bull;&nbsp;ألم&nbsp;البطن</p><p>&bull;&nbsp;تساقط&nbsp;الشعر&nbsp;على&nbsp;المدى&nbsp;القصير&nbsp;(في&nbsp;معظم&nbsp;الحالات&nbsp;سيعود&nbsp;نمو&nbsp;الشعرالطبيعي).</p><p>&bull;&nbsp;ألم&nbsp;في&nbsp;الظهر</p><p>&bull;&nbsp;الم&nbsp;المفاصل</p><p>&bull;&nbsp;دم&nbsp;في&nbsp;البول</p><p>&bull;&nbsp;الشعور&nbsp;بالتعب&nbsp;أو&nbsp;الضعف&nbsp;أو&nbsp;نقص&nbsp;الطاقة.</p><p>&nbsp;</p><p><strong>شائعة</strong>&nbsp;(قد&nbsp;تظهر&nbsp;لدى&nbsp;حتى&nbsp;1&nbsp;من&nbsp;كل&nbsp;10&nbsp;أشخاص):</p><p>&bull;&nbsp;التهاب&nbsp;المسالك&nbsp;البولية</p><p>&bull;&nbsp;نقص&nbsp;خلايا&nbsp;الدم&nbsp;البيضاء&nbsp;المصاحب&nbsp;للحمى&nbsp;والعدوى</p><p>&bull;&nbsp;الشعور&nbsp;بخدر،&nbsp;وخز،&nbsp;حرقان&nbsp;أو&nbsp;انخفاض&nbsp;درجة&nbsp;الإحساس&nbsp;في&nbsp;اليدين&nbsp;والقدمين</p><p>&bull;&nbsp;دوخة</p><p>&bull;&nbsp;صداع</p><p>&bull;&nbsp;انخفاض&nbsp;أو&nbsp;ارتفاع&nbsp;ضغط&nbsp;الدم</p><p>&bull;&nbsp;الشعور&nbsp;بعدم&nbsp;الراحة&nbsp;في&nbsp;المعدة،&nbsp;حرقة&nbsp;في&nbsp;القلب&nbsp;أو&nbsp;التجشؤ</p><p>&bull;&nbsp;آلام&nbsp;في&nbsp;المعدة</p><p>&bull;&nbsp;البواسير</p><p>&bull;&nbsp;تشنّج&nbsp;عضلي</p><p>&bull;&nbsp;التبول&nbsp;المؤلم&nbsp;أو&nbsp;المتكرر</p><p>&bull;&nbsp;سلس&nbsp;البول</p><p>&bull;&nbsp;أمراض&nbsp;أو مشاكل&nbsp;الكلى&nbsp;أو&nbsp;مشاكلها</p><p>&bull;&nbsp;قرحة&nbsp;في&nbsp;الفم&nbsp;أو&nbsp;في&nbsp;الشفاه</p><p>&bull;&nbsp;الالتهابات&nbsp;أو&nbsp;خطر&nbsp;العدوى</p><p>&bull;&nbsp;ارتفاع&nbsp;نسبة&nbsp;السكر&nbsp;في&nbsp;الدم</p><p>&bull;&nbsp;انخفاض&nbsp;البوتاسيوم&nbsp;في&nbsp;الدم</p><p>&bull;&nbsp;تشوش&nbsp;ذهني</p><p>&bull;&nbsp;الشعور&nbsp;بالقلق</p><p>&bull;&nbsp;شعور&nbsp;غير&nbsp;طبيعي&nbsp;أو&nbsp;فقدان&nbsp;الإحساس&nbsp;أو&nbsp;ألم&nbsp;في&nbsp;اليدين&nbsp;والقدمين</p><p>&bull;&nbsp;طنين&nbsp;في&nbsp;الأذن</p><p>&bull;&nbsp;مشكلة&nbsp;في&nbsp;التوازن</p><p>&bull;&nbsp;ضربات&nbsp;قلب&nbsp;سريعة&nbsp;أو&nbsp;غير&nbsp;منتظمة</p><p>&bull;&nbsp;جلطة&nbsp;دموية&nbsp;في&nbsp;الساق</p><p>&bull;&nbsp;شعور&nbsp;بالحرارة&nbsp;أو&nbsp;الاحمرار في&nbsp;الجلد</p><p>&bull;&nbsp;ألم&nbsp;في&nbsp;الفم&nbsp;أو&nbsp;الحلق</p><p>&bull;&nbsp;نزيف&nbsp;مستقيمي</p><p>&bull;&nbsp;احمرار&nbsp;الجلد</p><p>&bull;&nbsp;ألم&nbsp;عضلي</p><p>&bull;&nbsp;تورم&nbsp;في&nbsp;القدمين&nbsp;أو&nbsp;الساقين</p><p>&bull;&nbsp;قشعريرة.</p><p>&nbsp;</p><p><strong>غير&nbsp;شائعة&nbsp;</strong>(قد&nbsp;تظهر&nbsp;لدى&nbsp;حتى&nbsp;1&nbsp;من&nbsp;كل&nbsp;100&nbsp;شخص):</p><p>&bull;&nbsp;التهاب&nbsp;المثانة،&nbsp;والذي&nbsp;يمكن&nbsp;أن&nbsp;يحدث&nbsp;إذا سبق&nbsp;تعرضت&nbsp;مثانتك&nbsp;للعلاج&nbsp;الإشعاعي&nbsp;(التهابالمثانة&nbsp;بسبب&nbsp;ظاهرة&nbsp;استدعاء&nbsp;الإشعاع).</p><p>&nbsp;</p><p><strong>التكرار&nbsp;غير&nbsp;معروف</strong>&nbsp;(لا&nbsp;يمكن&nbsp;تقديره&nbsp;من&nbsp;البيانات&nbsp;المتاحة):</p><p>&bull;&nbsp;داء&nbsp;الرئة&nbsp;الخلالي&nbsp;(التهاب&nbsp;الرئتين&nbsp;يسبب&nbsp;السعال&nbsp;وصعوبة&nbsp;التنفس).</p><p>&nbsp;</p><p>الإبلاغ&nbsp;عن&nbsp;الأعراض&nbsp;الجانبية</p><p>إذا&nbsp;كنت&nbsp;تعاني&nbsp;من&nbsp;أي&nbsp;آثار&nbsp;جانبية،&nbsp;تحدث&nbsp;إلى&nbsp;طبيبك.&nbsp;يتضمن&nbsp;ذلك&nbsp;أي&nbsp;آثار&nbsp;جانبية&nbsp;محتملة&nbsp;غيرمذكورة&nbsp;في&nbsp;هذه&nbsp;النشرة.&nbsp;يمكنك&nbsp;أيضًا&nbsp;الإبلاغ&nbsp;عن&nbsp;الآثار&nbsp;الجانبية&nbsp;مباشرةً&nbsp;عبر&nbsp;نظام&nbsp;الإبلاغ&nbsp;الوطنيالمدرج&nbsp;في&nbsp;الملحق&nbsp;الخامس.&nbsp;من&nbsp;خلال&nbsp;الإبلاغ&nbsp;عن&nbsp;الآثار&nbsp;الجانبية،&nbsp;يمكنك&nbsp;المساعدة&nbsp;في&nbsp;توفير&nbsp;مزيدمن&nbsp;المعلومات&nbsp;حول&nbsp;سلامة&nbsp;هذا&nbsp;الدواء.</p><p>&nbsp;</p><p><strong>للإبلاغ&nbsp;عن&nbsp;أي&nbsp;آثار&nbsp;جانبية:</strong></p><p>&bull;&nbsp;المركز&nbsp;الوطني&nbsp;للتيقظ&nbsp;الدوائي&nbsp;(NPC):</p><p>-&nbsp;مركز&nbsp;اتصال&nbsp;الهيئة&nbsp;العامة&nbsp;للغذاء&nbsp;والدواء: 19999</p><p>- البريد&nbsp;الإكتروني:&nbsp;npc.drug@sfda.gov.sa</p><p>-&nbsp;موقع الويب:&nbsp;https://ade.sfda.gov.sa/</p><p>دول&nbsp;مجلس&nbsp;التعاون&nbsp;الخليجي&nbsp;الأخرى:</p><p>-&nbsp;يرجى&nbsp;الاتصال&nbsp;بالجهة&nbsp;المختصة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيفية&nbsp;تخزين&nbsp;أنافالين</strong></p><p>احفظ&nbsp;هذا&nbsp;الدواء&nbsp;بعيداً&nbsp;عن&nbsp;أنظار&nbsp;ومتناول&nbsp;أيدي&nbsp;الأطفال.</p><p>لا&nbsp;تستخدم&nbsp;هذا&nbsp;الدواء&nbsp;بعد&nbsp;تاريخ&nbsp;انتهاء&nbsp;الصلاحية&nbsp;المدون&nbsp;على&nbsp;الكرتون&nbsp;الخارجي&nbsp;وعلى&nbsp;ملصقالقنينات.&nbsp;يشير&nbsp;تاريخ&nbsp;انتهاء&nbsp;الصلاحية&nbsp;إلى&nbsp;اليوم&nbsp;الأخير&nbsp;من&nbsp;نفس&nbsp;الشهر.</p><p>لا&nbsp;يتطلب&nbsp;هذا&nbsp;المنتج&nbsp;الطبي&nbsp;أي&nbsp;شروط&nbsp;تخزين&nbsp;خاصة.</p><p>لا&nbsp;تقم بتجميده.</p><p>قنينات&nbsp;متعددة&nbsp;الجرعات:&nbsp;تم&nbsp;إثبات&nbsp;الاستقرار&nbsp;الكيميائي&nbsp;والفيزيائي&nbsp;والميكروبيولوجي&nbsp;للمحلول&nbsp;بعدالفتح&nbsp;الأول&nbsp;لمدة&nbsp;28&nbsp;يوماً&nbsp;في&nbsp;أقل&nbsp;من&nbsp;25&nbsp;درجة&nbsp;مئوية. أنافالين&nbsp;مناسب&nbsp;للاستخدام&nbsp;متعدد&nbsp;الجرعات.</p><p>المعلومات&nbsp;حول&nbsp;التخزين&nbsp;ووقت&nbsp;استخدام&nbsp;أنافالين&nbsp;بمجرد&nbsp;تخفيفه&nbsp;وجاهزيته&nbsp;للاستخدام،&nbsp;موضحة&nbsp;فيقسم&nbsp;&quot;المعلومات&nbsp;العملية&nbsp;للعاملين&nbsp;بالطب&nbsp;أو&nbsp;الرعاية&nbsp;الصحية&nbsp;حول&nbsp;تحضير&nbsp;أنافالين&nbsp;وإدارتهوالتعامل&nbsp;معه&quot;.</p><p>يجب&nbsp;التخلص&nbsp;من&nbsp;أي&nbsp;منتج&nbsp;غير&nbsp;مستخدم&nbsp;أو&nbsp;مواد&nbsp;نفايات&nbsp;وفقًا&nbsp;للمتطلبات&nbsp;المحلية.&nbsp;ومن&nbsp;شأن&nbsp;هذهالتدابير&nbsp;أن&nbsp;تساعد&nbsp;على&nbsp;حماية&nbsp;البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما&nbsp;يحتويه&nbsp;أنافالين</strong></p><p>المادة&nbsp;الفعالة&nbsp;هي&nbsp;كابازيتاكسيل.&nbsp;يحتوي&nbsp;مل&nbsp;واحد&nbsp;من&nbsp;محلول&nbsp;التسريب&nbsp;على&nbsp;كابازيتاكسيلمونوهيدرات&nbsp;أو&nbsp;ما&nbsp;يعادل&nbsp;10&nbsp;ملغ&nbsp;كابازيتاكسيل.</p><p>تحتوي&nbsp;كل&nbsp;قنينة&nbsp;4.5&nbsp;مل&nbsp;من&nbsp;محلول&nbsp;التسريب&nbsp;على&nbsp;كابازيتاكسيل&nbsp;مونوهيدرات&nbsp;أو&nbsp;لا&nbsp;مائي&nbsp;مكافئ&nbsp;لـ45&nbsp;ملغ&nbsp;كابازيتاكسيل.</p><p>تحتوي&nbsp;كل&nbsp;قنينة&nbsp;5&nbsp;مل&nbsp;من&nbsp;محلول&nbsp;التسريب&nbsp;على&nbsp;كابازيتاكسيل&nbsp;مونوهيدرات&nbsp;أو&nbsp;لا&nbsp;مائي&nbsp;مكافئ&nbsp;لـ50&nbsp;ملغ&nbsp;كابازيتاكسيل.</p><p>تحتوي&nbsp;كل&nbsp;قنينة&nbsp;6&nbsp;مل&nbsp;من&nbsp;محلول&nbsp;التسريب&nbsp;على&nbsp;كابازيتاكسيل&nbsp;مونوهيدرات&nbsp;أو&nbsp;لا&nbsp;مائي&nbsp;مكافئ&nbsp;لـ60&nbsp;ملغ&nbsp;كابازيتاكسيل.</p><p>يحتوي&nbsp;أنافالين 10 ملغ/ مل&nbsp;من&nbsp;محلول&nbsp;التسريب&nbsp;مملوء تمام.&nbsp;يضمن&nbsp;هذا&nbsp;الإفراط&nbsp;في&nbsp;الملء&nbsp;وجودحجم&nbsp;قابل&nbsp;للاستخراج&nbsp;4.5&nbsp;مل&nbsp;أو&nbsp;5&nbsp;مل&nbsp;أو&nbsp;6&nbsp;مل&nbsp;يحتوي&nbsp;على&nbsp;10&nbsp;ملغ/&nbsp;مل&nbsp;كابازيتاكسيل.</p><p>المكونات&nbsp;الأخرى&nbsp;هي&nbsp;بولي&nbsp;سوربات&nbsp;80؛&nbsp;ماكروغول.&nbsp;حمض&nbsp;الستريك؛&nbsp;والإيثانول&nbsp;اللامائي&nbsp;(انظرالقسم&nbsp;2 &quot;أنافالين&nbsp;يحتوي&nbsp;على&nbsp;الكحول&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف&nbsp;يبدو&nbsp;أنافالين&nbsp;وما&nbsp;هي&nbsp;محتويات&nbsp;العبوة</strong></p><p>أنافالين&nbsp;هو&nbsp;مركز&nbsp;لمحلول&nbsp;التسريب&nbsp;(تركيز&nbsp;معقم).</p><p>التركيز&nbsp;عبارة&nbsp;عن&nbsp;محلول&nbsp;زيتي&nbsp;صافٍ&nbsp;أصفر&nbsp;قليلاً.</p><p>عبوة&nbsp;واحدة&nbsp;من&nbsp;أنافالين&nbsp;تحتوي&nbsp;على:</p><p>قنين&nbsp;زجاجية&nbsp;شفافة&nbsp;مغلقة&nbsp;بسدادة&nbsp;مطاطية&nbsp;من&nbsp;البروموبوتيل&nbsp;باللون&nbsp;الرمادي&nbsp;وغطاء&nbsp;من&nbsp;الألومنيومبغطاء&nbsp;بلاستيكي&nbsp;قابل&nbsp;للقلب&nbsp;يحتوي&nbsp;على&nbsp;4.5&nbsp;مل&nbsp;(5&nbsp;مل&nbsp;أو&nbsp;6&nbsp;مل)&nbsp;مركّز.</p><p>قد&nbsp;يتم&nbsp;أو&nbsp;لا&nbsp;يتم&nbsp;تغليف&nbsp;القوارير&nbsp;في&nbsp;غلاف&nbsp;واقي.</p><p>قد&nbsp;لا&nbsp;يتم&nbsp;تسويق&nbsp;جميع&nbsp;أحجام&nbsp;العبوات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>صاحب&nbsp;ترخيص&nbsp;التسويق&nbsp;والشركة&nbsp;المصنعة</strong></p><p>صاحب&nbsp;ترخيص&nbsp;التسويق:</p><p>EVER&nbsp;Valinject&nbsp;GmbH</p><p>Oberburgau&nbsp;3&nbsp;</p><p>4866&nbsp;Unterach&nbsp;am&nbsp;Attersee</p><p>النمسا</p><p><strong>الصانع:</strong></p><p>EVER Pharma Jena GmbH</p><p>Otto-Schott-Strasse 15&nbsp;</p><p>07745 Jena&nbsp;</p><p>ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Feb 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Anavalin 10 mg/ml concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of the concentrate for solution for infusion contains cabazitaxel monohydrate or anhydrous equivalent to 10 mg cabazitaxel.
Each vial of 4.5 ml of concentrate for solution for infusion contains cabazitaxel monohydrate or anhydrous equivalent to 45 mg cabazitaxel.
Each vial of 5 ml of concentrate for solution for infusion contains cabazitaxel monohydrate or anhydrous equivalent to 50 mg cabazitaxel.
Each vial of 6 ml of concentrate for solution for infusion contains cabazitaxel monohydrate or anhydrous equivalent to 60 mg cabazitaxel
Anavalin 10 mg/ml concentrate for solution for infusion contains an overfill. This overfill ensures that there is extractable volume of 4.5 ml, 5 ml or 6 ml containing 10 mg/ml cabazitaxel.
Excipient with known effect
Each ml of concentrate for solution for infusion contains 197.5 mg of ethanol.
Each vial of 4.5 ml concentrate contains 888.8 mg of ethanol (19.75% w/v).
Each vial of 5 ml concentrate contains 987.5 mg of ethanol (19.75% w/v).
Each vial of 6 ml concentrate contains 1,185 mg of ethanol (19.75% w/v).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear slightly yellow oily solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anavalin&nbsp;in combination with prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel-containing regimen (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of&nbsp;Anavalin&nbsp;should be confined to units&nbsp;specialised&nbsp;in the administration of&nbsp;cytotoxics&nbsp;and it should only be administered under the supervision of a physician experienced in the use of anticancer chemotherapy. Facilities and equipment for the treatment of serious hypersensitivity reactions like hypotension and bronchospasm must be available (see section 4.4).</p><p>Premedication</p><p>The recommended premedication regimen should be performed at least 30 minutes prior to each administration of&nbsp;Anavalin&nbsp;with the following intravenous medicinal products to mitigate the risk and severity of hypersensitivity:</p><p>&bull; antihistamine (dexchlorpheniramine 5 mg or diphenhydramine 25 mg or equivalent),</p><p>&bull; corticosteroid (dexamethasone 8 mg or equivalent), and&nbsp;</p><p>&bull; H2 antagonist (ranitidine or equivalent) (see section 4.4).</p><p>Antiemetic prophylaxis is recommended and can be given orally or intravenously as needed.</p><p>Throughout the treatment, adequate hydration of the patient needs to be ensured, in order to prevent complications like renal failure.</p><p>Posology</p><p>The recommended dose of&nbsp;Anavalin&nbsp;is 25 mg/m2&nbsp;administered as a&nbsp;1 hour&nbsp;intravenous infusion every 3 weeks in combination with oral prednisone or prednisolone 10 mg administered daily throughout treatment.&nbsp;</p><p>Dose adjustments&nbsp;</p><p>Dose modifications should be made if patients experience the following adverse reactions (Grades refer to Common Terminology Criteria for Adverse Events [CTCAE 4.0]):</p><p>Table 1 - Recommended dose modifications for adverse reaction in patients treated with&nbsp;cabazitaxel</p><table><tbody><tr><td><p>Adverse reactions</p></td><td><p>Dose modification</p></td></tr><tr><td><p>Prolonged grade &ge;3 neutropenia (longer than 1 week) despite appropriate treatment including G-CSF</p></td><td><p>Delay treatment until neutrophil count is &gt;1,500 cells/mm3, then reduce&nbsp;cabazitaxel&nbsp;dose from 25 mg/m2&nbsp;to 20 mg/m2.&nbsp;</p></td></tr><tr><td><p>Febrile neutropenia or neutropenic infection</p></td><td><p>Delay treatment until improvement or resolution, and until neutrophil count is &gt;1,500 cells/mm3, then reduce&nbsp;cabazitaxel&nbsp;dose from 25 mg/m2&nbsp;to 20 mg/m2.</p></td></tr><tr><td><p>Grade &ge;3 diarrhoea or persisting diarrhoea despite appropriate treatment, including fluid and electrolytes replacement</p></td><td><p>Delay treatment until improvement or resolution, then reduce&nbsp;cabazitaxel&nbsp;dose from 25 mg/m2&nbsp;to 20 mg/m2.</p></td></tr><tr><td><p>Grade&nbsp;&gt;2 peripheral neuropathy&nbsp;</p></td><td><p>Delay treatment until improvement, then reduce&nbsp;cabazitaxel&nbsp;dose from 25 mg/m2&nbsp;to 20 mg/m2.</p></td></tr></tbody></table><p>If patients continue to experience any of these reactions at 20 mg/m2, further dose reduction to 15 mg/m2&nbsp;or discontinuation of&nbsp;Anavalin&nbsp;may be considered. Data in patients below the 20 mg/m2&nbsp;dose are limited.</p><p>Special populations</p><p>Patients with hepatic impairment</p><p>Cabazitaxel&nbsp;is extensively&nbsp;metabolised&nbsp;by the liver. Patients with mild hepatic impairment (total bilirubin &gt;1 to &le;1.5 x Upper Limit of Normal (ULN) or AST &gt;1.5 x ULN), should have&nbsp;cabazitaxel&nbsp;dose reduced to 20 mg/m2. Administration of&nbsp;cabazitaxel&nbsp;to patients with mild hepatic impairment should be undertaken with caution and close monitoring of safety.</p><p>In patients with moderate hepatic impairment (total bilirubin &gt;1.5 to &le; 3.0 x ULN), the maximum tolerated dose (MTD) was 15 mg/m2. If the treatment is envisaged in patients with moderate hepatic impairment the dose of&nbsp;cabazitaxel&nbsp;should not exceed 15 mg/m2. However, limited efficacy data are available at this dose.</p><p>Cabazitaxel&nbsp;should not be given to patients with severe hepatic impairment (total bilirubin &gt;3 x ULN) (see sections 4.3, 4.4 and 5.2).</p><p>Patients with renal impairment&nbsp;</p><p>Cabazitaxel&nbsp;is minimally excreted through the kidney. No dose adjustment is necessary in patients with renal impairment, not requiring hemodialysis. Patients presenting end stage renal disease (creatinine clearance (CLCR&lt; 15 mL/min/1.73 m2), by their condition and the limited amount of data available should be treated with caution and monitored carefully during treatment (see sections 4.4 and 5.2).</p><p>Elderly</p><p>No specific dose adjustment for the use of&nbsp;cabazitaxel&nbsp;in elderly patients is recommended (see also sections 4.4, 4.8 and 5.2).</p><p>Concomitant medicinal products use</p><p>Concomitant medicinal products that are strong inducers or strong inhibitors of CYP3A should be avoided. However, if patients require co-administration of a strong CYP3A inhibitor, a 25%&nbsp;cabazitaxel&nbsp;dose reduction should be considered (see sections 4.4 and 4.5).</p><p>Paediatric&nbsp;population</p><p>There is no relevant use of&nbsp;Anavalin&nbsp;in the&nbsp;paediatric&nbsp;population.&nbsp;</p><p>The safety and the efficacy of&nbsp;Anavalin&nbsp;in children and adolescents below 18 years of age have not been established (see section 5.1).&nbsp;</p><p>Method of administration</p><p>For instructions on preparation and administration of the product, see section 6.6.</p><p>PVC infusion containers and polyurethane infusion sets should not be used.</p><p>Anavalin&nbsp;must not be mixed with any other medicinal products than those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to cabazitaxel, to other taxanes, polysorbate 80 or any excipients listed in section 6.1.
• Neutrophil counts less than 1,500/mm3.
• Severe hepatic impairment (total bilirubin >3 x ULN).
• Concomitant vaccination with yellow fever vaccine (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions</p><p>All patients should be pre-medicated prior to the initiation of the infusion of&nbsp;cabazitaxel&nbsp;(see section 4.2).&nbsp;</p><p>Patients should be observed closely for hypersensitivity reactions especially during the first and second infusions. Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of&nbsp;cabazitaxel, thus facilities and equipment for the treatment of hypotension and bronchospasm should be available. Severe reactions can occur and may include&nbsp;generalised&nbsp;rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of&nbsp;cabazitaxel&nbsp;and appropriate therapy. Patients with a hypersensitivity reaction must stop treatment with&nbsp;Anavalin&nbsp;(see section 4.3).</p><p>Bone marrow suppression</p><p>Bone marrow suppression manifested as neutropenia,&nbsp;anaemia, thrombocytopenia, or pancytopenia may occur (see &ldquo;Risk of neutropenia&rdquo; and &ldquo;Anaemia&rdquo; in section 4.4 below).&nbsp;</p><p>Risk of neutropenia</p><p>Patients treated with&nbsp;cabazitaxel&nbsp;may receive prophylactic G-CSF, as per American Society of Clinical Oncology (ASCO) guidelines and/or current institutional guidelines, to reduce the risk or manage neutropenia complications (febrile neutropenia, prolonged neutropenia or neutropenic infection). Primary prophylaxis with G-CSF should be considered in patients with high-risk clinical features (age &gt;65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities) that predispose them to increased complications from prolonged neutropenia. The use of G-CSF has been shown to limit the incidence and severity of neutropenia.</p><p>Neutropenia is the most common adverse reaction of&nbsp;cabazitaxel&nbsp;(see section 4.8). Monitoring of complete blood counts is essential on a weekly basis during cycle 1 and before each treatment cycle thereafter so that the dose can be adjusted, if needed.</p><p>The dose should be reduced in case of febrile neutropenia, or prolonged neutropenia despite appropriate treatment (see section 4.2).</p><p>Patients should be re-treated only when neutrophils recover to a level &ge;1,500/mm3&nbsp;(see section 4.3).</p><p>Gastrointestinal disorders</p><p>Symptoms such as abdominal pain and tenderness, fever, persistent constipation,&nbsp;diarrhoea, with or without neutropenia, may be early manifestations of serious gastrointestinal toxicity and should be evaluated and treated promptly.&nbsp;Cabazitaxel&nbsp;treatment delay or discontinuation may be necessary.</p><p>Risk of nausea, vomiting,&nbsp;diarrhoea&nbsp;and dehydration</p><p>If patients experience&nbsp;diarrhoea&nbsp;following administration of&nbsp;cabazitaxel&nbsp;they may be treated with commonly used anti-diarrhoeal&nbsp;medicinal products. Appropriate measures should be taken to re-hydrate patients.&nbsp;Diarrhoea&nbsp;can occur more frequently in patients that have received prior&nbsp;abdomino-pelvic radiation. Dehydration is more common in patients aged 65 or older. Appropriate measures should be taken to rehydrate patients and to monitor and correct serum electrolyte levels, particularly potassium. Treatment delay or dose reduction may be necessary for grade &ge;3&nbsp;diarrhoea&nbsp;(see section 4.2). If patients experience nausea or vomiting, they may be treated with commonly used anti-emetics.</p><p>Risk of serious gastrointestinal reactions</p><p>Gastrointestinal (GI) hemorrhage and perforation, ileus, colitis, including fatal outcome, have been reported in patients treated with&nbsp;cabazitaxel&nbsp;(see section 4.8). Caution is advised with treatment of patients most at risk of developing gastrointestinal complications: those with neutropenia, the elderly, concomitant use of NSAIDs, anti-platelet therapy or anti-coagulants, and patients with a prior history of pelvic radiotherapy or gastrointestinal disease, such as ulceration and GI bleeding.</p><p>Peripheral neuropathy</p><p>Cases of peripheral neuropathy, peripheral sensory neuropathy (e.g.,&nbsp;paraesthesias,&nbsp;dysaesthesias) and peripheral motor neuropathy have been observed in patients receiving&nbsp;cabazitaxel. Patients under treatment with&nbsp;cabazitaxel&nbsp;should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop. Physicians should assess for the presence or worsening of neuropathy before each treatment. Treatment should be delayed until improvement of symptoms. The dose of&nbsp;cabazitaxel&nbsp;should be reduced from 25 mg/m2&nbsp;to 20 mg/m2&nbsp;for persistent grade&nbsp;&gt;2 peripheral neuropathy (see section 4.2).</p><p>Anaemia</p><p>Anaemia&nbsp;has been observed in patients receiving&nbsp;cabazitaxel&nbsp;(see section 4.8).&nbsp;Haemoglobinand&nbsp;haematocrit&nbsp;should be checked before treatment with&nbsp;cabazitaxel&nbsp;and if patients exhibit signs or symptoms of&nbsp;anaemia&nbsp;or blood loss. Caution is recommended in patients with&nbsp;haemoglobin&nbsp;&lt;10 g/dl and appropriate measures should be taken as clinically indicated.</p><p>Risk of renal failure&nbsp;</p><p>Renal disorders, have been reported in association with sepsis, severe dehydration due to&nbsp;diarrhoea, vomiting and obstructive uropathy. Renal failure including cases with fatal outcome has been observed. Appropriate measures should be taken to identify the cause and intensively treat the patients if this occurs.</p><p>Adequate hydration should be ensured throughout treatment with&nbsp;cabazitaxel. The patient should be advised to report any significant change in daily urinary volume immediately. Serum creatinine should be measured at baseline, with each blood count and whenever the patient reports a change in urinary output.&nbsp;Cabazitaxel&nbsp;treatment should be discontinued in case of any degradation of renal function to renal failure &ge;CTCAE 4.0 Grade 3.</p><p>Respiratory disorders</p><p>Interstitial pneumonia/pneumonitis and interstitial lung disease have been reported and may be associated with fatal outcome (see section 4.8).&nbsp;</p><p>If new or worsening pulmonary symptoms develop, patients should be closely monitored, promptly investigated, and appropriately treated. Interruption of&nbsp;cabazitaxel&nbsp;therapy is recommended until diagnosis is available. Early use of supportive care measures may help improve the condition. The benefit of resuming&nbsp;cabazitaxel&nbsp;treatment must be carefully evaluated.</p><p>Risk of cardiac arrhythmias</p><p>Cardiac arrhythmias have been reported, most commonly tachycardia and atrial fibrillation (see section 4.8).&nbsp;</p><p>Elderly</p><p>Elderly people (&ge;65 years of age) may be more likely to experience certain adverse reactions including neutropenia and febrile neutropenia (see section 4.8).</p><p>Patients with liver impairment&nbsp;</p><p>Treatment with&nbsp;Anavalin&nbsp;is contraindicated in patients with severe hepatic impairment (total bilirubin &gt; 3 x ULN) (See sections 4.3 and 5.2).</p><p>Dose should be reduced for patients with mild (total bilirubin &gt;1 to &le;1.5 x ULN or AST &gt;1.5 x ULN), hepatic impairment (see sections 4.2 and 5.2).</p><p>Interactions&nbsp;</p><p>Co-administration with strong CYP3A inhibitors should be avoided since they may increase the plasma concentrations of&nbsp;cabazitaxel&nbsp;(see sections 4.2 and 4.5). If co-administration with a&nbsp;strong CYP3A inhibitor cannot be avoided, close monitoring for toxicity and a&nbsp;cabazitaxeldose reduction should be considered (see sections 4.2 and 4.5).&nbsp;</p><p>Co-administration with strong CYP3A inducers should be avoided since they may decrease plasma concentrations of&nbsp;cabazitaxel&nbsp;(see sections 4.2 and 4.5).&nbsp;</p><p>Excipients</p><p>This medicinal product contains&nbsp;197.5&nbsp;mg ethanol per ml.</p><p>&nbsp;</p><p>Vial 4.5 ml</p><p>This medicine contains 888.8 mg of alcohol (ethanol) in each vial. The amount of 4.5 ml in this medicine is equivalent to&nbsp;22.5 ml beer or 9.4 ml wine.&nbsp;</p><p>&nbsp;</p><p>Vial 5 ml</p><p>This medicine contains 987.5 mg of alcohol (ethanol) in each vial. The amount of 5 ml in this medicine is equivalent to&nbsp;25 ml beer or&nbsp;10.4 ml wine.&nbsp;</p><p>&nbsp;</p><p>Vial 6 ml</p><p>This medicine contains 1185 mg of alcohol (ethanol) in each vial. The amount of 6 ml in this medicine is equivalent to 30&nbsp;ml beer or&nbsp;12.5&nbsp;ml wine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In vitro&nbsp;studies have shown that&nbsp;cabazitaxel&nbsp;is mainly&nbsp;metabolised&nbsp;through CYP3A (80% to 90%) (see section 5.2).</p><p>CYP3A inhibitors</p><p>Repeated administration of ketoconazole (400 mg once daily), a strong CYP3A inhibitor, resulted in a 20% decrease in&nbsp;cabazitaxel&nbsp;clearance corresponding to a 25% increase in AUC.&nbsp;Therefore,&nbsp;concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) should be avoided as an increase of plasma concentrations of&nbsp;cabazitaxel&nbsp;may occur (see sections 4.2 and 4.4).&nbsp;</p><p>Concomitant administration of&nbsp;aprepitant, a moderate CYP3A inhibitor, had no effect on&nbsp;cabazitaxel&nbsp;clearance.</p><p>CYP3A inducers</p><p>Repeated administration of rifampin (600 mg once daily), a strong CYP3A inducer, resulted in an increase in&nbsp;cabazitaxel&nbsp;clearance of 21% corresponding to a decrease in AUC of 17%.&nbsp;</p><p>Therefore,&nbsp;concomitant administration of strong CYP3A inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin,&nbsp;rifapentin, phenobarbital) should be avoided as a decrease of plasma concentrations of&nbsp;cabazitaxel&nbsp;may occur (see sections 4.2 and 4.4). In addition, patients should also refrain from taking St. John&#39;s Wort.</p><p>OATP1B1&nbsp;</p><p>In vitro,&nbsp;cabazitaxel&nbsp;has also been shown to inhibit the transport proteins of the Organic Anion Transport Polypeptides OATP1B1. The risk of interaction with OATP1B1 substrates (e.g. statins, valsartan, repaglinide) is possible, notably during the infusion duration (1 hour) and up to 20 minutes after the end of the infusion. A time interval of 12 hours is recommended before the infusion and at least 3 hours after the end of infusion before administering the OATP1B1 substrates.</p><p>Vaccinations</p><p>Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents may result in serious or fatal infections. Vaccination with a live attenuated vaccine should be avoided in patients receiving&nbsp;cabazitaxel. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are no data from the use of&nbsp;cabazitaxel&nbsp;in pregnant women. Studies in animals have shown reproductive toxicity at&nbsp;maternotoxic&nbsp;doses (see section 5.3) and that&nbsp;cabazitaxelcrosses the placenta barrier (see section 5.3). As with other cytotoxic medicinal products,&nbsp;cabazitaxel&nbsp;may cause&nbsp;foetal&nbsp;harm in exposed pregnant women.</p><p>Cabazitaxel&nbsp;is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>Breast-feeding</p><p>Available pharmacokinetics data in animals have shown excretion of&nbsp;cabazitaxel&nbsp;and its metabolites in milk (see section 5.3). A risk to the suckling child cannot be excluded.</p><p>Cabazitaxel&nbsp;should not be used during breast-feeding.</p><p>Fertility</p><p>Animal studies showed that&nbsp;cabazitaxel&nbsp;affected reproductive system in male rats and dogs without any functional effect on fertility (see section 5.3). Nevertheless, considering the pharmacological activity of&nbsp;taxanes, their genotoxic potential and effect of several compounds of this class on fertility in animal studies, effect on male fertility could not be excluded in human.</p><p>Due to potential effects on male gametes and to potential exposure via seminal liquid, men treated with&nbsp;cabazitaxel&nbsp;should use effective contraception throughout treatment and are recommended to continue this for up to 6 months after the last dose of&nbsp;cabazitaxel. Due to potential exposure via seminal liquid, men treated with&nbsp;cabazitaxel&nbsp;should prevent contact with the ejaculate by another person throughout treatment. Men being treated with&nbsp;cabazitaxelare advised to seek advice on conservation of sperm prior to treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cabazitaxel&nbsp;may influence the ability to drive and use machines as it may cause fatigue and dizziness. Patients should be advised not to drive or use machines if they experience these adverse reactions during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of safety profile</p><p>The safety of&nbsp;cabazitaxel&nbsp;in combination with prednisone or prednisolone was evaluated in 371 patients with metastatic castration resistant prostate cancer who were treated with 25 mg/m2&nbsp;cabazitaxel&nbsp;once every three weeks in a&nbsp;randomised&nbsp;open label, controlled phase III study. Patients received a median duration of 6 cycles of&nbsp;cabazitaxel.&nbsp;</p><p>The most commonly (&ge;10%) occurring adverse reactions in all grades were&nbsp;anaemia&nbsp;(97.3%), leukopenia (95.7%), neutropenia (93.5%), thrombocytopenia (47.4%), and&nbsp;diarrhoea&nbsp;(46.6%). The most commonly (&ge;5%) occurring grade &ge;3 adverse reactions in the&nbsp;cabazitaxel&nbsp;group were neutropenia (81.7%), leukopenia (68.2%),&nbsp;anaemia&nbsp;(10.5%), febrile neutropenia (7.5%),&nbsp;diarrhoea&nbsp;(6.2%).&nbsp;</p><p>Discontinuation of treatment due to adverse reactions occurred in 68 patients (18.3%) receiving&nbsp;cabazitaxel. The most common adverse reactions leading to&nbsp;cabazitaxeldiscontinuation was neutropenia.</p><p>Tabulated list of adverse reactions</p><p>Adverse reactions are listed in table 2 according to MedDRA system organ class and frequency categories. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Intensity of the adverse reactions is graded according to CTCAE 4.0 (grade &ge;3 = G&ge;3). Frequencies are based on all grades and defined as: very common (&ge;1/10);&nbsp;common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>Table 2: Reported adverse reactions and&nbsp;haematological&nbsp;abnormalities with&nbsp;cabazitaxel&nbsp;in combination with prednisone or prednisolone in the TROPIC study (n=371)</p><table><tbody><tr><td><p>System Organ Class</p></td><td><p>Adverse reaction</p></td><td colspan="2"><p>All grades</p><p>n (%)</p></td><td><p>Grade&gt;3</p><p>n (%)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Very common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Septic shock</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>4 (1.1)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Sepsis</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>4 (1.1)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Cellulitis</p></td><td><p>&nbsp;</p></td><td><p>6 (1.6)</p></td><td><p>2 (0.5)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Urinary tract infection</p></td><td><p>&nbsp;</p></td><td><p>27 (7.3)</p></td><td><p>4 (1.1)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Influenza</p></td><td><p>&nbsp;</p></td><td><p>11 (3)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Cystitis</p></td><td><p>&nbsp;</p></td><td><p>10 (2.7)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Upper respiratory tract infection</p></td><td><p>&nbsp;</p></td><td><p>10 (2.7)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Herpes zoster</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Candidiasis</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>0</p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>Neutropeniaa*</p></td><td><p>347 (93.5)</p></td><td><p>&nbsp;</p></td><td><p>303 (81.7)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Anaemia&nbsp;a</p></td><td><p>361 (97.3)</p></td><td><p>&nbsp;</p></td><td><p>39 (10.5)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Leukopeniaa</p></td><td><p>355 (95.7)</p></td><td><p>&nbsp;</p></td><td><p>253 (68.2)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Thrombocytopeniaa</p></td><td><p>176 (47.4)</p></td><td><p>&nbsp;</p></td><td><p>15 (4)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Febrile neutropenia</p></td><td><p>&nbsp;</p></td><td><p>28 (7.5)</p></td><td><p>28 (7.5)</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Hypersensitivity</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Anorexia</p></td><td><p>59 (15.9)</p></td><td><p>&nbsp;</p></td><td><p>3 (0.8)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dehydration</p></td><td><p>&nbsp;</p></td><td><p>18 (4.9)</p></td><td><p>8 (2.2)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hyperglycaemia</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>3 (0.8)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hypokalemia</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>2 (0.5)</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p>Anxiety</p></td><td><p>&nbsp;</p></td><td><p>11 (3)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Confusional state</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Dysgeusia</p></td><td><p>41 (11.1)</p></td><td><p>&nbsp;</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Neuropathy peripheral</p></td><td><p>&nbsp;</p></td><td><p>30 (8.1)</p></td><td><p>2 (0.5)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Peripheral sensory neuropathy</p></td><td><p>&nbsp;</p></td><td><p>20 (5.4)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dizziness</p></td><td><p>&nbsp;</p></td><td><p>30 (8.1)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Headache</p></td><td><p>&nbsp;</p></td><td><p>28 (7.5)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Paraesthesia</p></td><td><p>&nbsp;</p></td><td><p>17 (4.6)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Lethargy</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hypoaesthesia</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Sciatica</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>Conjunctivitis</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Lacrimation increased</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>Tinnitus</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vertigo</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>Cardiac disorders*</p></td><td><p>Atrial fibrillation</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>2 (0.5)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Tachycardia</p></td><td><p>&nbsp;</p></td><td><p>6 (1.6)</p></td><td><p>0</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>Hypotension</p></td><td><p>&nbsp;</p></td><td><p>20 (5.4)</p></td><td><p>2 (0.5)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Deep vein thrombosis</p></td><td><p>&nbsp;</p></td><td><p>8 (2.2)</p></td><td><p>7 (1.9)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hypertension</p></td><td><p>&nbsp;</p></td><td><p>6 (1.6)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Orthostatic hypotension</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hot flush</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Flushing</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>0</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Dyspnoea</p></td><td><p>44 (11.9)</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Cough</p></td><td><p>40 (10.8)</p></td><td><p>&nbsp;</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Oropharyngeal pain</p></td><td><p>&nbsp;</p></td><td><p>13 (3.5)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pneumonia</p></td><td><p>&nbsp;</p></td><td><p>9 (2.4)</p></td><td><p>6 (1.6)</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Diarrhoea</p></td><td><p>173 (46.6)</p></td><td><p>&nbsp;</p></td><td><p>23 (6.2)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Nausea</p></td><td><p>127 (34.2)</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Vomiting</p></td><td><p>84 (22.6)</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Constipation</p></td><td><p>76 (20.5)</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abdominal pain</p></td><td><p>43 (11.6)</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dyspepsia</p></td><td><p>&nbsp;</p></td><td><p>25 (6.7)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abdominal pain upper</p></td><td><p>&nbsp;</p></td><td><p>20 (5.4)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Haemorrhoids</p></td><td><p>&nbsp;</p></td><td><p>14 (3.8)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Gastroesophageal reflux disease</p></td><td><p>&nbsp;</p></td><td><p>12 (3.2)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Rectal haemorrhage</p></td><td><p>&nbsp;</p></td><td><p>8 (2.2)</p></td><td><p>2 (0.5)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dry mouth</p></td><td><p>&nbsp;</p></td><td><p>8 (2.2)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Abdominal distension</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Alopecia</p></td><td><p>37 (10)</p></td><td><p>&nbsp;</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dry skin</p></td><td><p>&nbsp;</p></td><td><p>9 (2.4)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Erythema</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Back pain</p></td><td><p>60 (16.2)</p></td><td><p>&nbsp;</p></td><td><p>14 (3.8)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Arthralgia</p></td><td><p>39 (10.5)</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pain in extremity</p></td><td><p>&nbsp;</p></td><td><p>30 (8.1)</p></td><td><p>6 (1.6)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Muscle spasms</p></td><td><p>&nbsp;</p></td><td><p>27 (7.3)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Myalgia</p></td><td><p>&nbsp;</p></td><td><p>14 (3.8)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Musculoskeletal chest pain</p></td><td><p>&nbsp;</p></td><td><p>11 (3)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Flank pain</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td><td><p>3 (0.8)</p></td></tr><tr><td><p>Renal and urinary disorders&nbsp;</p></td><td><p>Acute renal failure</p></td><td><p>&nbsp;</p></td><td><p>8 (2.2)</p></td><td><p>6 (1.6)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Renal failure</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td><td><p>6 (1.6)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dysuria</p></td><td><p>&nbsp;</p></td><td><p>25 (6.7)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Renal colic&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Haematuria</p></td><td><p>62 (16.7)</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pollakiuria</p></td><td><p>&nbsp;</p></td><td><p>13 (3.5)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hydronephrosis</p></td><td><p>&nbsp;</p></td><td><p>9 (2.4)</p></td><td><p>3 (0.8)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Urinary retention</p></td><td><p>&nbsp;</p></td><td><p>9 (2.4)</p></td><td><p>3 (0.8)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Urinary incontinence</p></td><td><p>&nbsp;</p></td><td><p>9 (2.4)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Ureteric obstruction</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td><td><p>5 (1.3)</p></td></tr><tr><td><p>Reproductive system and breast disorders</p></td><td><p>Pelvic pain</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>Fatigue</p></td><td><p>136 (36.7)</p></td><td><p>&nbsp;</p></td><td><p>18 (4.9)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Asthenia</p></td><td><p>76 (20.5)</p></td><td><p>&nbsp;</p></td><td><p>17 (4.6)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pyrexia</p></td><td><p>45 (12.1)</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Peripheral oedema</p></td><td><p>&nbsp;</p></td><td><p>34 (9.2)</p></td><td><p>2 (0.5)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Mucosal inflammation</p></td><td><p>&nbsp;</p></td><td><p>22 (5.9)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pain</p></td><td><p>&nbsp;</p></td><td><p>20 (5.4)</p></td><td><p>4 (1.1)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Chest pain</p></td><td><p>&nbsp;</p></td><td><p>9 (2.4)</p></td><td><p>2 (0.5)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Oedema</p></td><td><p>&nbsp;</p></td><td><p>7 (1.9)</p></td><td><p>1 (0.3)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Chills</p></td><td><p>&nbsp;</p></td><td><p>6 (1.6)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Malaise</p></td><td><p>&nbsp;</p></td><td><p>5 (1.3)</p></td><td><p>0</p></td></tr><tr><td><p>Investigations</p></td><td><p>Weight decreased</p></td><td><p>&nbsp;</p></td><td><p>32 (8.6)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Aspartate aminotransferase increased</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Transaminases increased</p></td><td><p>&nbsp;</p></td><td><p>4 (1.1)</p></td><td><p>0</p></td></tr></tbody></table><p>a&nbsp;based-on laboratory&nbsp;values</p><p>* see detailed section below</p><p>Description of selected adverse reactions</p><p>Neutropenia, and associated clinical events&nbsp;</p><p>Incidence of grade &ge;3 neutropenia based on laboratory data was 81.7%. The incidence of grade &ge;3 clinical neutropenia and febrile neutropenia adverse reactions were 21.3% and 7.5% respectively. Neutropenia was the most common adverse reaction leading to medicinal product discontinuation (2.4%).</p><p>Neutropenic complications included neutropenic infections (0.5%), neutropenic sepsis (0.8%), and septic shock (1.1%), which in some cases resulted in a fatal outcome.</p><p>The use of G-CSF has been shown to limit the incidence and severity of neutropenia (see sections 4.2 and 4.4).</p><p>Cardiac disorders and arrhythmias</p><p>All Grade events among cardiac disorders were more common on&nbsp;cabazitaxel&nbsp;of which 6 patients (1.6%) had Grade &ge;3 cardiac arrhythmias. The incidence of tachycardia on&nbsp;cabazitaxel&nbsp;was 1.6%, none of which were Grade &ge;3. The incidence of atrial fibrillation was 1.1% in the&nbsp;cabazitaxel&nbsp;group. Cardiac failure events were more common on&nbsp;cabazitaxel, the event term being reported for 2 patients (0.5%). One patient in the&nbsp;cabazitaxel&nbsp;group died from cardiac failure. Fatal ventricular fibrillation was reported in 1 patient (0.3%), and cardiac arrest in 2 patients (0.5%). None were considered related by the investigator.&nbsp;</p><p>Haematuria</p><p>Haematuria&nbsp;all grades frequency was 20.8% at 25 mg/m2&nbsp;in EFC11785 study (see section 5.1). Confounding causes such as disease progression, instrumentation, infection or anticoagulation/NSAID/aspirin therapy were identified in nearly two thirds of the cases.</p><p>Other laboratory abnormalities</p><p>The incidence of grade &ge;3&nbsp;anaemia, increased AST, ALT, and bilirubin based on laboratory abnormalities were 10.5%, 0.7%, 0.9%, and 0.6%, respectively.</p><p>Gastrointestinal disorders</p><p>Colitis, enterocolitis, gastritis, neutropenic enterocolitis have been observed. Gastrointestinal hemorrhage and perforation, ileus and intestinal obstruction have also been reported (see section 4.4).</p><p>Respiratory disorders</p><p>Cases of interstitial pneumonia/pneumonitis and interstitial lung disease, sometimes fatal have been reported with an unknown frequency (cannot be estimated from the available data) (see section 4.4).</p><p>Renal and urinary disorders&nbsp;</p><p>Cystitis due to radiation recall phenomenon, including&nbsp;haemorrhagic&nbsp;cystitis, were reported uncommonly.</p><p>Paediatric&nbsp;population</p><p>See section 4.2</p><p>Other special populations</p><p>Elderly population&nbsp;</p><p>Among the 371 patients treated with&nbsp;cabazitaxel&nbsp;in the prostate cancer study, 240 patients were 65 years or over including 70 patients older than 75 years.&nbsp;</p><p>The following adverse reactions reported at rates &ge;5% higher in patients 65 years of age or greater compared to younger patients were fatigue (40.4% versus 29.8%), clinical neutropenia (24.2% versus 17.6%), asthenia (23.8% versus 14.5%), pyrexia (14.6% versus 7.6%), dizziness (10.0% versus 4.6%), urinary tract infection (9.6% versus 3.1%) and dehydration (6.7% versus 1.5%), respectively.</p><p>The incidence of the following grade &ge;3 adverse reactions were higher in patients &ge;65 years of age compared to younger patients; neutropenia based on laboratory abnormalities (86.3% versus 73.3%), clinical neutropenia (23.8% versus 16.8%) and febrile neutropenia (8.3% versus 6.1%) (see sections 4.2 and 4.4).&nbsp;</p><p>Of the 595 patients treated with&nbsp;cabazitaxel&nbsp;25 mg/m2&nbsp;in the prostate cancer EFC 11785 study, 420 patients were 65 years or over. The adverse reactions reported at rates of at least 5% higher in patients 65 years of age or greater compared to younger patients were&nbsp;diarrhoea(42.9% vs. 32.6%), fatigue (30.2% vs. 19.4%), asthenia (22.4% vs. 13.1%), constipation (20.2% vs. 12.6%), clinical neutropenia (12.9% vs. 6.3%), febrile neutropenia (11.2% vs. 4.6%) and&nbsp;dyspnoea&nbsp;(9.5% vs. 3.4%).</p><p>Reporting of suspected adverse reactions</p><p>&bull;&nbsp;The National Pharmacovigilance Centre&nbsp;(NPC):</p><p>&nbsp;</p><p>&ndash;&nbsp;SFDA Call Center:&nbsp;19999</p><p>&ndash;&nbsp;E-mail:&nbsp;npc.drug@sfda.gov.sa&nbsp;</p><p>&ndash;&nbsp;Website:&nbsp;https://ade.sfda.gov.sa/</p><p>Reporting suspected adverse reactions after&nbsp;authorisation&nbsp;of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via&nbsp;the national reporting system&nbsp;listed in&nbsp;Appendix V.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote to&nbsp;cabazitaxel. The anticipated complications of overdose would consist of exacerbation of adverse reactions as bone marrow suppression and gastrointestinal disorders.</p><p>In case of overdose, the patient should be kept in a&nbsp;specialised&nbsp;unit and closely monitored. Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents,&nbsp;taxanes, ATC code: L01CD04</p><p>Mechanism of action</p><p>Cabazitaxel&nbsp;is an antineoplastic agent that acts by disrupting the microtubular network in cells.&nbsp;Cabazitaxel&nbsp;binds to tubulin and promotes the assembly of tubulin into microtubules while simultaneously inhibiting their disassembly. This leads to the&nbsp;stabilisation&nbsp;of microtubules, which results in the inhibition of mitotic and interphase cellular functions.</p><p>Pharmacodynamic effects</p><p>Cabazitaxel&nbsp;demonstrated a broad spectrum of&nbsp;antitumour&nbsp;activity against advanced human&nbsp;tumours&nbsp;xenografted in mice.&nbsp;Cabazitaxel&nbsp;is active in docetaxel-sensitive&nbsp;tumours. In addition,&nbsp;cabazitaxel&nbsp;demonstrated activity in&nbsp;tumour&nbsp;models insensitive to chemotherapy including docetaxel.</p><p>Clinical efficacy and safety</p><p>The efficacy and safety of&nbsp;cabazitaxel&nbsp;in combination with prednisone or prednisolone were evaluated in a&nbsp;randomised, open-label, international, multi-center, phase III study (EFC6193 study), in patients with metastatic castration resistant prostate cancer&nbsp;previously&nbsp;treated with a docetaxel containing regimen.&nbsp;</p><p>Overall survival (OS) was the primary efficacy endpoint of the study.&nbsp;</p><p>Secondary endpoints included Progression Free Survival [PFS (defined as time from randomization to&nbsp;tumour&nbsp;progression, Prostatic Specific Antigen (PSA) progression, pain progression, or death due to any cause, whichever occurred first],&nbsp;Tumour&nbsp;Response Rate based on Response Evaluation Criteria in Solid&nbsp;Tumours&nbsp;(RECIST), PSA Progression (defined as a &ge;25% increase or &gt;50% in PSA non-responders or responders respectively), PSA response (declines in serum PSA levels of at least 50%), pain progression [assessed using the Present Pain Intensity (PPI) scale from the McGill-Melzack&nbsp;questionnaire and an Analgesic Score (AS)] and pain response (defined as 2-point greater reduction from baseline median PPI with no concomitant increase in AS, or reduction of &ge;50% in analgesic use from baseline mean AS with no concomitant increase in pain).</p><p>A total of 755 patients were&nbsp;randomised&nbsp;to receive either&nbsp;cabazitaxel&nbsp;25 mg/m2&nbsp;intravenously every 3 weeks for a maximum of 10 cycles with prednisone or prednisolone 10 mg orally daily (n=378), or to receive mitoxantrone 12 mg/m2&nbsp;intravenously every 3 weeks for a maximum of 10 cycles with prednisone or prednisolone 10 mg orally daily (n=377).&nbsp;</p><p>This study included patients over 18 years of age with metastatic castration resistant prostate cancer either measurable by RECIST criteria or non-measurable disease with rising PSA levels or appearance of new lesions, and Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. Patients had to have neutrophils &gt;1,500/mm3, platelets &gt;100,000/mm3,&nbsp;haemoglobin&nbsp;&gt;10 g/dl, creatinine &lt;1.5 x ULN, total bilirubin &lt;1 x ULN, AST and ALT &lt;1.5 x ULN.&nbsp;</p><p>Patients with a history of congestive heart failure, or myocardial infarction within last 6 months, or patients with uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension were not included in the study.</p><p>Demographics, including age, race, and ECOG performance status (0 to 2), were balanced between the treatment arms. In the&nbsp;cabazitaxel&nbsp;group, the mean age was 68 years, range (46-92) and the racial distribution was 83.9% Caucasian, 6.9% Asian/Oriental, 5.3% Black and 4% Others.</p><p>The median number of cycles was 6 in the&nbsp;cabazitaxel&nbsp;group and 4 in the mitoxantrone group. The number of patients who completed the study treatment (10 cycles) was respectively 29.4% and 13.5% in the&nbsp;cabazitaxel&nbsp;group and in the comparator group.&nbsp;</p><p>Overall survival was significant longer with&nbsp;cabazitaxel&nbsp;compared to mitoxantrone (15.1 months versus 12.7 respectively), with a 30% reduction in the risk of death compared to mitoxantrone (see table 3 and figure 1).&nbsp;</p><p>A sub-group of 59 patients received prior cumulative dose of docetaxel &lt;225 mg/m&sup2; (29 patients in&nbsp;cabazitaxel&nbsp;arm, 30 patients in mitoxantrone arm). There was no significant difference in overall survival in this group of patients (HR (95%CI) 0.96 (0.49-1.86)).</p><p>Table 3 - Efficacy of&nbsp;cabazitaxel&nbsp;in EFC6193 study in the treatment of patients with metastatic castration resistant prostate cancer</p><table><tbody><tr><td><p>&nbsp;</p></td><td><p>Cabazitaxel&nbsp;+ prednisone</p><p>n=378</p></td><td><p>mitoxantrone + prednisone</p><p>n=377</p></td></tr><tr><td><p>Overall survival</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Number of patients with deaths (%)</p></td><td><p>234 (61.9%)</p></td><td><p>279 (74%)</p></td></tr><tr><td><p>Median survival (months) (95% CI)</p></td><td><p>15.1 (14.1-16.3)</p></td><td><p>12.7 (11.6-13.7)</p></td></tr><tr><td><p>Hazard Ratio (HR)1&nbsp;(95% CI)</p></td><td colspan="2"><p>0.70 (0.59-0.83)</p></td></tr><tr><td><p>p-value</p></td><td colspan="2"><p>&lt;0.0001</p></td></tr></tbody></table><p>1HR estimated using Cox model; a hazard ratio of less than 1&nbsp;favours&nbsp;Cabazitaxel</p><p>Figure 1: Kaplan Meier overall survival curves (EFC6193)</p><p><img src="blob:https://sdi.sfda.gov.sa/77053026-b06d-4e1e-bc42-89cd2e0c4c9d" /></p><p>There was an improvement in PFS in the&nbsp;cabazitaxel&nbsp;arm compared to mitoxantrone arm, 2.8 (2.4-3.0) months versus 1.4 (1.4-1.7) respectively, HR (95%CI) 0.74 (0.64-0.86), p&lt;0.0001.&nbsp;</p><p>There was a significant higher rate of&nbsp;tumour&nbsp;response of 14.4% (95%CI: 9.6-19.3) in patients in the&nbsp;cabazitaxel&nbsp;arm compared to 4.4% (95%CI: 1.6-7.2) for patients in the mitoxantrone arm, p=0.0005.</p><p>PSA secondary endpoints were positive in the&nbsp;cabazitaxel&nbsp;arm. There was a median PSA progression of 6.4 months (95%CI: 5.1-7.3) for patients in&nbsp;cabazitaxel&nbsp;arm, compared to 3.1 months (95%CI: 2.2-4.4) in the mitoxantrone arm, HR 0.75 months (95%CI: 0.63-0.90), p=0.0010. The PSA response was 39.2% in patients on&nbsp;cabazitaxel&nbsp;arm (95%CI: 33.9-44.5) versus 17.8% of patients on mitoxantrone (95%CI: 13.7-22.0), p=0.0002.&nbsp;</p><p>There was no statistical difference between both treatment arms in pain progression and pain response.</p><p>In a non-inferiority, multicenter, multinational, randomized, open label phase III study (EFC11785 study), 1200 patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing regimen, were randomized to receive either&nbsp;cabazitaxel&nbsp;25 mg/m2&nbsp;(n=602) or 20 mg/m2&nbsp;(n=598) dose. Overall survival (OS) was the primary efficacy end-point.</p><p>The study met its primary objective of demonstrating the non-inferiority of&nbsp;cabazitaxel&nbsp;20 mg/m2&nbsp;in comparison with 25 mg/m2&nbsp;(see table 4). A statistically significantly higher percentage (p&lt;0.001) of patients showed a PSA response in the 25 mg/m2&nbsp;group (42.9%) compared to the 20 mg/m2&nbsp;group (29.5%). A statistically significantly higher risk of PSA progression in patients with the 20 mg/m2&nbsp;dose with respect to the 25 mg/m2&nbsp;dose was observed (HR 1.195 ; 95%CI: 1.025 to 1.393). There was no statistically difference with regards to the other secondary endpoints (PFS,&nbsp;tumour&nbsp;and pain response,&nbsp;tumour&nbsp;and pain progression, and four subcategories of FACT-P).</p><p>Table 4 - Overall survival in EFC11785 study in&nbsp;cabazitaxel&nbsp;25 mg/m2&nbsp;arm versus&nbsp;cabazitaxel20 mg/m2&nbsp;arm (Intent-to&ndash;treat analysis) &ndash; Efficacy primary endpoint</p><table><tbody><tr><td><p>&nbsp;</p></td><td><p>CBZ20+PRED</p><p>n=598</p></td><td><p>CBZ25+PRED</p><p>n=602</p></td></tr><tr><td><p>Overall Survival</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Number of deaths, n (%)</p></td><td><p>497 (83.1 %)</p></td><td><p>501 (83.2%)</p></td></tr><tr><td><p>Median survival (95% CI) (months)&nbsp;</p></td><td><p>13.4 (12.19 to 14.88)</p></td><td><p>14.5 (13.47 to 15.28)</p></td></tr><tr><td><p>Hazard Ratioa</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>versus CBZ25+PRED</p></td><td><p>1.024</p></td><td><p>-</p></td></tr><tr><td><p>1-sided 98.89% UCI</p></td><td><p>1.184</p></td><td><p>-</p></td></tr><tr><td><p>1-sided 95% LCI</p></td><td><p>0.922</p></td><td><p>-</p></td></tr></tbody></table><p>CBZ20=Cabazitaxel&nbsp;20 mg/m2, CBZ25=Cabazitaxel&nbsp;25 mg/m2, PRED=Prednisone/Prednisolone&nbsp;</p><p>CI=confidence interval, LCI=lower bound of the confidence interval, UCI=upper bound of the confidence interval&nbsp;</p><p>a&nbsp;Hazard ratio is estimated using a Cox Proportional Hazards regression model. A hazard ratio &lt; 1 indicates a lower risk of&nbsp;cabazitaxel&nbsp;20 mg/m2&nbsp;with respect to 25 mg/m2.&nbsp;</p><p>The safety profile of&nbsp;cabazitaxel&nbsp;25 mg/m2&nbsp;observed in study EFC11785 was qualitatively and quantitatively similar to that observed in the study EFC6193. Study EFC11785 demonstrated a better safety profile for the&nbsp;cabazitaxel&nbsp;20 mg/m2&nbsp;dose.</p><p>Table 5 - Summary of safety data for&nbsp;cabazitaxel&nbsp;25 mg/m2&nbsp;arm versus&nbsp;cabazitaxel&nbsp;20 mg/m2arm in EFC11785 study</p><table><tbody><tr><td><p>&nbsp;</p></td><td><p>CBZ20+PRED</p><p>n=580</p></td><td><p>CBZ25+PRED</p><p>n=595</p></td></tr><tr><td><p>Median number of cycles/ median duration of treatment</p></td><td><p>6/ 18 weeks</p></td><td><p>7/ 21 weeks</p></td></tr><tr><td><p>Number of patients with dose reduction</p><p>n (%)</p></td><td><p>From 20 to 15 mg/m2: 58 (10.0%)</p><p>From 15 to 12 mg/m2: 9 (1.6%)</p></td><td><p>From 25 to 20 mg/m2: 128 (21.5%)</p><p>From 20 to 15 mg/m2: 19 (3.2%)</p><p>From 15 to 12 mg/m2: 1 (0.2%)</p></td></tr><tr><td colspan="2"><p>All grade adverse reactions&nbsp;a&nbsp;(%)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>30.7</p></td><td><p>39.8</p></td></tr><tr><td><p>Nausea</p></td><td><p>24.5</p></td><td><p>32.1</p></td></tr><tr><td><p>Fatigue</p></td><td><p>24.7</p></td><td><p>27.1</p></td></tr><tr><td><p>Haematuria</p></td><td><p>14.1</p></td><td><p>20.8</p></td></tr><tr><td><p>Asthenia</p></td><td><p>15.3</p></td><td><p>19.7</p></td></tr><tr><td><p>Decreased appetite</p></td><td><p>13.1</p></td><td><p>18.5</p></td></tr><tr><td><p>Vomiting</p></td><td><p>14.5</p></td><td><p>18.2</p></td></tr><tr><td><p>Constipation</p></td><td><p>17.6</p></td><td><p>18.0</p></td></tr><tr><td><p>Back pain</p></td><td><p>11.0</p></td><td><p>13.9</p></td></tr><tr><td><p>Clinical neutropenia</p></td><td><p>3.1</p></td><td><p>10.9</p></td></tr><tr><td><p>Urinary tract infection</p></td><td><p>6.9</p></td><td><p>10.8</p></td></tr><tr><td><p>Peripheral sensory neuropathy</p></td><td><p>6.6</p></td><td><p>10.6</p></td></tr><tr><td><p>Dysgeusia</p></td><td><p>7.1</p></td><td><p>10.6</p></td></tr><tr><td colspan="2"><p>Grade &ge; 3 adverse reactions&nbsp;b&nbsp;(%)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Clinical neutropenia</p></td><td><p>2.4</p></td><td><p>9.6</p></td></tr><tr><td><p>Febrile neutropenia</p></td><td><p>2.1</p></td><td><p>9.2</p></td></tr><tr><td colspan="2"><p>Haematological abnormalities&nbsp;c&nbsp;(%)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Grade &ge; 3 neutropenia</p></td><td><p>41.8</p></td><td><p>73.3</p></td></tr><tr><td><p>Grade &ge; 3 anaemia</p></td><td><p>9.9</p></td><td><p>13.7</p></td></tr><tr><td><p>Grade &ge; 3 thrombocytopenia</p></td><td><p>2.6</p></td><td><p>4.2</p></td></tr></tbody></table><p>CBZ20=Cabazitaxel&nbsp;20 mg/m2, CBZ25=Cabazitaxel&nbsp;25 mg/m2, PRED=Prednisone/Prednisolone&nbsp;</p><p>a&nbsp;All grade adverse reactions with an incidence higher than 10%&nbsp;</p><p>b&nbsp;Grade &ge; 3 adverse reactions with an incidence higher than 5%&nbsp;</p><p>c&nbsp;Based on laboratory values</p><p>Paediatric&nbsp;population</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with&nbsp;cabazitaxel&nbsp;in all subsets of the&nbsp;paediatric&nbsp;population in the indication of prostate cancer (see section 4.2 for information on&nbsp;paediatric&nbsp;use).</p><p>Cabazitaxel&nbsp;was evaluated in an open label, multi-center Phase 1/2 study conducted in a total of 39&nbsp;paediatric&nbsp;patients (aged between 4 to&nbsp;18 years for the phase 1 part of the study and between 3 to 16 years for the phase 2 part of the study). The phase 2 part did not demonstrate efficacy of&nbsp;cabazitaxel&nbsp;as single agent in&nbsp;paediatric&nbsp;population with recurrent or refractory diffuse intrinsic pontine glioma (DIPG) and&nbsp;high grade&nbsp;glioma (HGG) treated at 30 mg/m&sup2;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A population pharmacokinetic analysis was carried out in 170 patients including patients with advanced solid&nbsp;tumours&nbsp;(n=69), metastatic breast cancer (n=34) and metastatic prostate cancer (n=67). These patients received&nbsp;cabazitaxel&nbsp;at doses of 10 to 30 mg/m2&nbsp;weekly or every 3 weeks.</p><p>Absorption&nbsp;</p><p>After 1-hour intravenous administration at 25 mg/m2&nbsp;cabazitaxel&nbsp;in patients with metastatic prostate cancer (n=67), the&nbsp;Cmax&nbsp;was 226 ng/ml (Coefficient of Variation (CV): 107%) and was reached at the end of the 1-hour infusion (Tmax). The mean AUC was 991&nbsp;ng.h/ml (CV: 34%).</p><p>No major deviation to the dose proportionality was observed from 10 to 30 mg/m&sup2; in patients with advanced solid&nbsp;tumours&nbsp;(n=126).</p><p>Distribution</p><p>The volume of distribution (Vss) was 4870 l (2640 l/m&sup2; for a patient with a median BSA of 1.84 m&sup2;) at steady state.&nbsp;</p><p>In vitro, the binding of&nbsp;cabazitaxel&nbsp;to human serum proteins was 89-92% and was not saturable up to 50,000 ng/ml, which covers the maximum concentration observed in clinical studies.&nbsp;Cabazitaxel&nbsp;is mainly bound to human serum albumin (82.0%) and lipoproteins (87.9% for HDL, 69.8% for LDL, and 55.8% for VLDL). The&nbsp;in vitro&nbsp;blood-to-plasma concentration ratios in human blood ranged from 0.90 to 0.99 indicating that&nbsp;cabazitaxel&nbsp;was equally distributed between blood and plasma.&nbsp;</p><p>Biotransformation</p><p>Cabazitaxel&nbsp;is extensively&nbsp;metabolised&nbsp;in the liver (&gt;95%), mainly by the CYP3A isoenzyme (80% to 90%).&nbsp;Cabazitaxel&nbsp;is the main circulating compound in human plasma. Seven metabolites were detected in plasma (including 3 active metabolites issued form O-demethylations), with the main one accounting for 5% of parent exposure. Around 20 metabolites of&nbsp;cabazitaxel&nbsp;are excreted into human urine and&nbsp;faeces.&nbsp;</p><p>Based on&nbsp;in vitro studies, the potential risk of inhibition by&nbsp;cabazitaxel&nbsp;at clinically relevant concentrations is possible towards medicinal products that are mainly substrate of CYP3A.</p><p>However,&nbsp;a clinical study has shown that&nbsp;cabazitaxel&nbsp;(25 mg/m2 administered as a single 1-hour infusion) did not modify the plasma levels of midazolam, a probe substrate of CYP3A. Therefore, at therapeutic doses, co-administration of CYP3A substrates with&nbsp;cabazitaxel&nbsp;to patients is not expected to have any clinical impact.&nbsp;</p><p>There is no potential risk of inhibition of medicinal products that are substrates of other CYP enzymes (1A2, 2B6, 2C9, 2C8, 2C19, 2E1, and 2D6) as well as no potential risk of induction by&nbsp;cabazitaxel&nbsp;on medicinal products that are substrates of CYP1A, CYP2C9, and CYP3A.&nbsp;Cabazitaxel&nbsp;did not inhibit&nbsp;in vitro&nbsp;the major biotransformation pathway of warfarin into 7-hydroxywarfarin, which is mediated by CYP2C9. Therefore, no pharmacokinetic interaction of&nbsp;cabazitaxel&nbsp;on warfarin is expected&nbsp;in vivo.&nbsp;</p><p>In vitro&nbsp;cabazitaxel&nbsp;did not inhibit Multidrug-Resistant Proteins (MRP): MRP1 and MRP2 or Organic Cation Transporter (OCT1).&nbsp;Cabazitaxel&nbsp;inhibited the transport of P-glycoprotein (PgP) (digoxin,&nbsp;vinblastin), Breast-Cancer-Resistant-Proteins (BCRP) (methotrexate) and Organic Anion Transporting Polypeptide OATP1B3 (CCK8) at concentrations at least 15 fold what is observed in clinical setting while it inhibited the transport of OATP1B1 (estradiol-17&beta;-glucuronide) at concentrations only 5 fold what is observed in clinical setting.&nbsp;Therefore,the risk of interaction with substrates of MRP, OCT1,&nbsp;PgP, BCRP and OATP1B3 is unlikely&nbsp;in vivo&nbsp;at the dose of 25 mg/m2. The risk of interaction with OATP1B1 transporter is possible, notably during the infusion duration (1 hour) and up to 20 minutes after the end of the infusion (see section 4.5).&nbsp;</p><p>Elimination</p><p>After a 1-hour intravenous infusion [14C]-cabazitaxel&nbsp;at 25 mg/m2&nbsp;in patients, approximately 80% of the administered dose was eliminated within 2 weeks.&nbsp;Cabazitaxel&nbsp;is mainly excreted in the&nbsp;faeces&nbsp;as numerous metabolites (76% of the dose); while renal excretion of&nbsp;cabazitaxeland metabolites account for less than 4% of the dose (2.3% as unchanged medicinal product in urine).</p><p>Cabazitaxel&nbsp;had a high plasma clearance of 48.5 l/h (26.4 l/h/m&sup2; for a patient with a median BSA of 1.84 m&sup2;) and a long terminal half-life of 95 hours.&nbsp;</p><p>Special populations</p><p>Elderly patients</p><p>In the population pharmacokinetic analysis in 70 patients of 65 years and older (57 from 65 to 75 and 13 patients above 75), no age effect on the pharmacokinetics of&nbsp;cabazitaxel&nbsp;was observed.</p><p>Paediatric&nbsp;patients</p><p>Safety and effectiveness of&nbsp;Anavalin&nbsp;have not been established in children and adolescents below 18 years of age.</p><p>Hepatic impairment&nbsp;</p><p>Cabazitaxel&nbsp;is eliminated primarily via liver metabolism.</p><p>A dedicated study in 43 cancer patients with hepatic impairment showed no influence of mild (total bilirubin &gt;1 to &le;1.5 x ULN or AST &gt;1.5 x ULN) or moderate (total bilirubin &gt;1.5 to &le;3.0 x ULN) hepatic impairment on&nbsp;cabazitaxel&nbsp;pharmacokinetics. The maximum tolerated dose (MTD) of&nbsp;cabazitaxel&nbsp;was 20 and 15 mg/m2, respectively.</p><p>In 3 patients with severe hepatic impairment (total bilirubin &gt;3 ULN), a 39% decrease in clearance was observed when compared to patients with mild hepatic impairment, indicating some effect of severe hepatic impairment on&nbsp;cabazitaxel&nbsp;pharmacokinetics. The MTD of&nbsp;cabazitaxel&nbsp;in patients with severe hepatic impairment was not established.</p><p>Based on safety and tolerability data,&nbsp;cabazitaxel&nbsp;dose should be reduced in patients with mild hepatic impairment (see sections 4.2, 4.4).&nbsp;Anavalin&nbsp;is contraindicated in patients with severe hepatic impairment (see section 4.3).</p><p>Renal impairment</p><p>Cabazitaxel&nbsp;is minimally excreted via the kidney (2.3% of the dose). A population pharmacokinetic analysis carried out in 170 patients that included 14 patients with moderate renal impairment (creatinine clearance in the range of 30 to 50 ml/min) and 59 patients with mild renal impairment (creatinine clearance in the range of 50 to 80 ml/min) showed that mild to moderate renal impairment did not have meaningful effects on the pharmacokinetics of&nbsp;cabazitaxel. This was confirmed by a dedicated comparative pharmacokinetic study in solid cancer patients with normal renal function (8 patients), moderate (8 patients) and severe (9 patients) renal impairment, who received several cycles of&nbsp;cabazitaxel&nbsp;in single IV infusion up to 25 mg/m2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions not observed in clinical studies, but seen in dogs after single dose, 5-day and weekly administration at exposure levels lower than clinical exposure levels and with possible relevance to clinical use were arteriolar/periarterolar&nbsp;necrosis in the liver, bile&nbsp;ductulehyperplasia and/or hepatocellular necrosis (see section 4.2).</p><p>Adverse reactions not observed in clinical studies&nbsp;but seen in rats during repeat-dose toxicity studies at exposure levels higher than clinical exposure levels and with possible relevance to clinical use were eye disorders characterized by subcapsular lens fiber swelling/degeneration. These effects were partially reversible after 8 weeks.</p><p>Carcinogenicity studies have not been conducted with&nbsp;cabazitaxel.</p><p>Cabazitaxel&nbsp;did not induce mutations in the bacterial reverse mutation (Ames) test. It was not clastogenic in an&nbsp;in vitro&nbsp;test in human lymphocytes (no induction of structural chromosomal&nbsp;aberration but it increased number of polyploid cells) and induced an increase of micronuclei in the&nbsp;in vivo&nbsp;test in rats.&nbsp;However,&nbsp;these genotoxicity findings are inherent to the pharmacological activity of the compound (inhibition of tubulin depolymerization) and have been observed with medicinal products exhibiting the same pharmacological activity.</p><p>Cabazitaxel&nbsp;did not affect mating performances or fertility of treated male rats. However, in repeated-dose toxicity studies, degeneration of seminal vesicle and seminiferous tubule atrophy in the testis were observed in rats, and testicular degeneration (minimal epithelial single cell necrosis in epididymis), was observed in dogs. Exposures in animals were similar or lower than those seen in humans receiving clinically relevant doses of&nbsp;cabazitaxel.</p><p>Cabazitaxel&nbsp;induced&nbsp;embryofoetal&nbsp;toxicity in female rats treated intravenously once daily from gestational days 6 through 17 linked with maternal toxicity and consisted of&nbsp;foetaldeaths and decreased mean&nbsp;foetal&nbsp;weight associated with delay in skeletal ossification. Exposures in animals were lower than those seen in humans receiving clinically relevant doses of&nbsp;cabazitaxel.&nbsp;Cabazitaxel&nbsp;crossed the placenta barrier in rats.</p><p>In rats,&nbsp;cabazitaxel&nbsp;and its metabolites are excreted in maternal milk at a quantity up to 1.5% of administered dose over 24 hours.&nbsp;</p><p>Environmental Risk Assessment (ERA)</p><p>Results of environmental risk assessment studies indicated that use of&nbsp;cabazitaxel&nbsp;will not cause significant risk to the aquatic environment (see section 6.6 for disposal of unused product).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polysorbate 80</p><p>Ethanol, anhydrous</p><p>Macrogol</p><p>Citric acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>PVC infusion containers or polyurethane infusion sets should not be used for the preparation and administration of the infusion solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
2 years
After first opening
Multi-dose vials: Chemical, physical and microbiological stability of the solution after first opening has been demonstrated for 28 days below 25°C. Anavalin is suitable for multi-dose use.
After dilution in the infusion bag/bottle
Chemical and physical stability of the infusion solution has been demonstrated for 48 hours at below 25°C and for 14 days at refrigerated conditions.
From a microbiological point of view, the infusion solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours below 25°C, unless dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p><p>Do not&nbsp;freeze.</p><p>For storage conditions after&nbsp;first opening&nbsp;and dilution&nbsp;of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One pack contains one vial of concentrate&nbsp;for solution for infusion:</p><p>Clear, glass vial closed with a grey&nbsp;bromobutyl&nbsp;rubber stopper sealed with an&nbsp;aluminium&nbsp;cap covered with a plastic flip-off cap.</p><p>&nbsp;</p><p>Pack sizes:​1 x 4,5 ml (45 mg)</p><p>​​1 x 5 ml (50 mg)</p><p>​​1 x 6 ml (60 mg)</p><p>Vials may or may not be sheathed in a protective sleeve.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anavalin&nbsp;should only be prepared and administered by personnel trained in handling cytotoxic agents. Pregnant staff should not handle the product. As for any other antineoplastic agent, caution should be exercised when handling and preparing&nbsp;Anavalin&nbsp;solutions, taking into account the use of containment devices, personal protective equipment (e.g.&nbsp;gloves), and preparation procedures. If&nbsp;Anavalin,&nbsp;at any step of its handling, should&nbsp;come into contact withthe skin, wash immediately and thoroughly with soap and water. If it should&nbsp;come into contact with&nbsp;mucous membranes, wash immediately and thoroughly with water.</p><p>Read this&nbsp;ENTIRE&nbsp;section carefully.&nbsp;Anavalin&nbsp;requires&nbsp;ONE&nbsp;dilution prior to administration.&nbsp;Follow the preparation instructions provided below.</p><p>The following dilution process must be carried out in an aseptic manner for preparing the solution for infusion.</p><p>More than one vial of the concentrate may be necessary to administer the prescribed dose.</p><p>Dilution for infusion</p><p>Step 1:&nbsp;Aseptically withdraw the required amount of&nbsp;concentrate (10 mg/ml of&nbsp;cabazitaxel), with a graduated syringe fitted&nbsp;with a needle. As an example, a dose of 45 mg&nbsp;Anavalinwould require 4.5 ml of the&nbsp;concentrate.</p><p>Anavalin&nbsp;10 mg/ml&nbsp;concentrate for solution for infusion&nbsp;contains an overfill. This overfill ensures that there is extractable volume of 4.5 ml, 5 ml or 6 ml containing 10 mg/ml&nbsp;cabazitaxel.</p><p>Step 2:&nbsp;Inject in a sterile PVC-free container of either&nbsp;5% glucose solution or sodium chloride9 mg/ml (0.9%) solution for infusion. The&nbsp;concentration of the infusion solution should bebetween 0.10 mg/ml and 0.26 mg/ml.</p><p>Step 3:&nbsp;Remove the syringe and mix the content of the&nbsp;infusion bag or bottle manually using a rocking&nbsp;motion.</p><p>Step 4:&nbsp;As with all parenteral products, the resulting infusion solution should be visually inspected prior to use. As the infusion solution is supersaturated, it may crystallize over time. In this case, the solution must not be used and should be discarded.</p><p>The infusion solution should be used immediately. However, in-use storage time can be longer under specific conditions mentioned in section 6.3.&nbsp;</p><p>Do not use PVC infusion containers or polyurethane infusion sets for the preparation and administration of&nbsp;Anavalin.</p><p>Anavalin&nbsp;must not be mixed with any other medicinal products than those mentioned.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee, Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>